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ABSTRACT

Impacts of Rift Valley Fever virus:
a One Health approach to assess burden and inform prevention and control options
by Catherine C. Machalaba

Advisor: Jean Grassman, PhD MS
Background: Rift Valley Fever (RVF) is a climate-sensitive emerging zoonotic disease associated
with large-scale livestock production losses and human disease burden in Sub-Saharan Africa and
the Middle East. While recognized as a key One Health issue based on its transmission dynamics
involving human, animal and environmental determinants, there has been poor coordination
between sectors to reduce the risk and impact of RVF. Efforts to counter the disease remain largely
reactive, presenting an ongoing threat to local and global health security. The intent of this
dissertation was to improve understanding of the burden of RVF across society and to identify
entry points for practical and cost-effective interventions at global, national, and local scales.
Methods: For Aim 1, we quantified global impacts using official and unofficial reports of human
and animal disease and deaths from RVF. We assessed univariate correlation between RVF
reporting and broad country-level predictor variables for African nations and describe country
development characteristics as well as review major capacity and implementation gaps. In Aim 2,
we conducted the first national cost analysis for RVF in South Africa, utilizing a One Health
approach to combine data from multiple sectors (agriculture, health, environment, tourism, and
finance) and identify the type, magnitude, and distribution of expenditures and losses in outbreaks
and inter-epidemic periods between 2003-2018. Aim 3 focuses on actionable policy
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recommendations, using a survey on RVF prevention and control practices and willingness to pay
(WTP) measures to improve understanding of economic behaviors of farm owners, the primary
decision-maker for RVF vaccine uptake, in South Africa’s Free State and Northern Cape
provinces.
Results: In aim 1, we find that a total of 5,228 suspected human cases and 987 deaths, and 72,960
animal cases and 17,810 deaths, were officially reported in 32 countries between 2000-2019. Of
the twelve country-level predictor variables assessed, a higher number of RVF publications was
significantly associated with higher odds of official reporting of RVF 2000-2019 (OR=1.5),
whereas higher level of political stability and absence of violence was protective against RVF
reporting (OR=.39), as was higher percentage of population with access to electricity (OR=.97)
(all p<.05). On average, countries reporting RVF in Africa have high dependence on livestock,
and face major economic, infrastructure, and capacity deficits, which can be expected to affect
implementation and efficacy of RVF prevention, detection and response campaign.
In Aim 2, we find that between 2003-2018, RVF was associated with at least US$120.6 million
in expenditures and losses in South Africa. The majority of impacts were incurred during epidemic
periods. The burden of disease from RVF was estimated at 680.913 Disability-Adjusted Life
Years, with the majority from premature death. Productivity losses and medical and public health
spending accounted for approximately 5% of total costs. Overall, costs were concentrated in the
livestock sector, representing 85.5% of costs. Other affected sectors incurring losses included
finance (via avoided tax revenue) and environment (wildlife products).
In Aim 3, 90% of farms in our sample of 120 commercial livestock farms in South Africa’s
Free State and Northern Cape provinces were willing to pay something annually to avoid RVF
losses, with an overall mean of $727.23 per year. Higher mean WTP to avoid animal losses from
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RVF was significantly associated with higher number of domestic animals and wool farming
(p<.05). There was also a significant difference in WTP to vaccinate herds against RVF based on
level of risk of RVF circulating in mosquitoes in their province or farm (p<.000). Most farms
indicated they would take measures other than or in addition to vaccination if they thought risk of
RVF was high in their province, including insecticide/dip (90.65%) and antibiotics (28.04%).
Several barriers and enablers were identified for uptake of livestock vaccination against RVF.
Among the barriers, approximately half the farms thought vaccine supply was sufficient in general,
whereas less than one-fourth thought it was sufficient during an outbreak.
Discussion: Over the past two decades, RVF has affected multiple continents. The lack of a
comprehensive reporting system for animal and human disease burden makes tracking official
estimates challenging. A comparison to published estimates suggests wide under-reporting of
RVF. In terms of prevention and control practices, affected countries face several major economic,
capacity, and infrastructure barriers that may affect uptake and effectiveness of vaccination.
Encouragingly, from our national- and farm-level analyses in South Africa, we find that there is
some existing investment in RVF in interepidemic periods, and that there may be supply and
demand-side practices that may be supported by low-cost or multi-disease interventions, such as
enhanced risk communication and tracking of vaccine availability. Our findings can be paired with
further willingness to pay studies of other payer groups to identify optimal resource allocation
options. Future macro- and micro-costing studies can improve precision of data inputs. While the
need for a One Health approach has been articulated for improved understanding of the risks of
RVF, our findings demonstrate how a One Health lens also has utility in assessing impacts to
identify a broader range of affected stakeholders and inform coordinated action to address both
animal and human disease and wider societal impacts.
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CHAPTER 1 – INTRODUCTION
Overview
Despite global progress in reducing the burden of infectious disease, emerging and endemic
zoonotic and vector-borne diseases remain a local and global threat to public health. Zoonoses
ranging from diseases traced back centuries or longer, such as Rabies, to recently-emerging or
novel pathogens such as Rift Valley Fever virus and Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV2), account for an estimated 2.4 billion human cases and 2.2 million
deaths per year.1,2
Rift Valley Fever (RVF) is an internationally-notifiable zoonotic and vector-borne viral disease
impacting multiple countries over recent decades. The health and economic impacts have
manifested in variable but significant ways.3 For example, outbreaks of RVF have caused largescale animal die-offs and human illness in Africa and the Middle East with socio-economic
impacts ranging from production losses, international trade bans, food insecurity, threats to
livelihoods, tourism declines, and costs of surveillance and control.3-5 For livestock diseases in
particular, such as RVF, the impact may be disproportionately felt by populations at high risk of
poverty from potential loss of economic solvency, presenting a fundamental sustainable
development challenge.6 RVF infections may also cause long-term complications (ocular,
neurologic) with possible resulting workforce productivity losses and other impacts (e.g. on quality
of life).7,8
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Public Health Significance
Although efforts to address emerging disease threats in humans are typically viewed in the
domain of the public health sector and largely focus on containment and control, accounting for
impacts to other sectors (e.g. agriculture, environment, tourism) can more comprehensively
account for the true cost to society and identify sectors that drive risk to better target prevention
at the source.9 The nature of zoonotic diseases requires a more integrated approach to assess how
drivers and impacts of risk are distributed to inform cost-effective resource allocation strategies
for risk management.10,11 While RVF has been prioritized for human vaccine research, it also
warrants greater attention to its socioeconomic determinants and consequences to understand the
scope of its impacts and tailor interventions to those most vulnerable to its effects.
The disease represents a persistent public and animal health threat in South Africa and much
of the African continent. The first detection in South Africa was during a major epizootic in 1950,
which caused over 100,000 livestock deaths.12 Major subsequent outbreaks in the country have
occurred in 1974-75 and 2008-2011, with the 2008-2011 outbreak responsible for over 300
confirmed human cases and 25 known deaths and over 14,000 documented livestock cases
accompanied by livestock abortion storms.13,14 However, smaller outbreaks are suspected to occur
during inter-epidemic periods but go unreported.15 As livestock constitutes over 40% of
agricultural gross domestic product in the country and provides important contributions to
economic solvency, it is critical to define a strategy for managing the threat of RVF.16 More
consistent control strategies may better help prevent both large-scale and smaller outbreaks and
their damages. While a livestock vaccine is available, uptake is inconsistent from year-to-year,
region, and by farm type (e.g. commercial, small producers, and communal). Farmers,
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veterinarians and abattoir workers are at elevated risk for infection based on exposures to infected
animals and their products.14
RVFV is a priority pathogen given its severity and concern over its international spread
(whether accidental or intentional). RVF (family Phenuiviridae) is classified on the Category A
Priority Pathogen list by the NIH for its Biodefense Research.17 RVFV is also listed as a biological
agent under the Federal Select Agent Program.18 There is no vaccine approved for human use, and
the main treatment for animals and humans is primarily supportive therapy.19 It is a reportable
disease for both the World Health Organization (WHO) and the World Organisation for Animal
Health (OIE).20,21
RVF is a climate-sensitive disease, and risk may be affected by climate and other
environmental changes. Extreme weather and rainfall anomalies are thought to be a major factor
in outbreak risk.22,23 Sub-Saharan Africa is projected as particularly vulnerable to climate change,
with myriad potential health effects.24 There are over thirty known competent vector species for
RVF.12 Changing climate or other environmental conditions can potentially increase or shift the
suitable habitat for RVF vectors and introduce emergence factors (such as mosquito hatching in
response to rainfall anomaly events), creating new risks over the coming decades.25
The complex human health, animal health, ecological and socio-economic dimensions of RVF
require a “One Health” approach.26 The frequent lack of understanding of pathogen maintenance
and transmission factors requires collaboration between human, animal and environmental health
sectors to elucidate risk factors and the effectiveness of risk management practices.27 To date, the
limited understanding of RVF transmission cycles does not allow for reliable prediction and
implementation of effective prevention and control measures, requiring a long-term (5, 10, 20-year
or more) time horizon.28 The costs and benefits to different sectors during major outbreaks, as well
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as inter-epidemic periods, warrant consideration to optimize prevention and control strategies.
While analyses to date focus on aggregate burden of endemic zoonoses, the increasing risk of
novel disease appearance and spread warrants assessment of the cumulative health impacts of
emerging zoonoses. While known prevention strategies often exist, efforts to control zoonotic
disease at their sources remain limited and country-specific, frequently favoring reactive, ad hoc
response to each new outbreak.29 Preliminary findings suggest that a coordinated approach to RVF
can help detect associations between risk factors and may be cost-saving for human and animal
surveillance and disease investigations.30
Broadly, social and environmental determinants of health affect vulnerability for both exposure
and impacts associated with zoonoses including RVF.31-35 Occupation represents a major risk
factor (particularly farm and abattoir workers and veterinarians) through contact practices with
infected livestock.25,36 Ecosystem type (dambos or pans subject to flooding) and weather anomaly
(temperature and rainfall) have also been identified as important predictors of RVF outbreaks.22,3742

Within these social and environmental factors, sub-factors play a role in infection risk (e.g., use

of personal protective equipment by employees). Thus, broad interventions are currently the most
appropriate for national, provincial and local policy consideration, and thus will be investigated in
this study. Finally, international, national, provincial and local protocols and policies may
potentially affect awareness, willingness to pay, and application of disease prevention or control
measures; these may also be different among farm type. Associated policies may also serve as
mediators for exposures and impacts. Public health concern may also prompt action in other sectors
that may mediate risk and incur costs, while also potentially avoiding future damages. The current
reactive stance that is typical for RVF and other zoonotic diseases is the baseline for comparing
interventions through factors that can mediate risk.
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Previous studies have identified high variability by country in proportional economic impacts
of RVF to affected sectors.3,9,32 However, these studies have not applied a ‘One Health’ lens, with
limited sectors and fields included in their data collection to date. Few studies have quantified the
economic impact of emerging zoonotic diseases beyond either the human health or agricultural
sector, and analysis and uptake of prevention and control strategies for emerging zoonoses remains
limited in general. In South Africa, only partial impacts of the 2008-2011 RVF outbreak have been
estimated to date, limited to segments of the livestock sector.43 In line with the 2016
recommendations of the Second Panel for Cost-Effectiveness in Health and Medicine,44 this
unique study will take a societal perspective to provide more comprehensive understanding of
wide-ranging impacts and inform possible solutions. Considering the relevance of multiple sectors
and stakeholder groups (e.g. entities responsible for human health, agriculture, environment,
tourism, vaccine production) through a One Health approach affords a broader view of direct and
indirect disease impacts not typically considered. Thus, this study is likely to provide more
comprehensive understanding of impacts through being inclusive of more sectors.
This dissertation study focused on impacts at global, national (South Africa), and provincial
levels, leveraging a direct link to data and partnerships from the largest study elucidating RVF
ecology and epidemiology to date (the U.S. Defense Threat Reduction Agency (DTRA)-funded
“Understanding Rift Valley Fever in the Republic of South Africa” project) to enhance validity
and relevance for policy action. The focus on South Africa in two chapters was also strategic given
the nation’s leadership capacity on emerging disease diagnostics in the region, as well as the link
to the South African government-owned institution (Onderstepoort Biological Products) as the
main producer and supplier of the RVF vaccine for the country and most of Africa. Pricing and
production volume may be informed by the findings of this project to optimize supply and demand,
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at least for use in two high-risk provinces in the South Africa. Using economic measures to
maximize public health and economic outcomes is especially timely given the multi-sectoral
attention to epidemic and pandemic preparedness under country-based One Health platforms and
the strong potential to inform WHO-guided National Action Plans for Health Security.45 More
systematic and comprehensive analysis of country-level health and economic costs of disease and
potential value of disease prevention may also motivate multisectoral action on other key priority
communicable and non-communicable diseases.
The aims of this study build on one another to examine: i) recent RVF burden, distribution,
and overall development gaps and trends for prevention and control; ii) the type, magnitude, and
distribution of sectoral and societal costs from RVF in South Africa; and iii) barriers, enablers and
willingness to pay for prevention to avoid losses from RVF in South Africa. The findings have
direct policy relevance for management of RVF and promote a ‘whole-of-society’ approach to
prevention and control of zoonotic disease.

Specific Aims and Hypotheses
While largely viewed as rare public health emergencies, the impacts of recent emerging infectious
disease outbreaks, particularly those of animal origin (“zoonoses”), often extend far beyond the
health sector and are on the scale of other major local, national, regional or global disasters and
economic crises.46-49 The frequency and cost of these events are generally recognized as increasing,
yet to date have not been not systematically assessed, particularly in terms of their cumulative
impacts and distribution. Characterizing impacts and understanding the capacity context at
regional and country level can help inform measures to prevent or reduce future impacts. This
dissertation assessed global impacts of RVF over epidemic and inter-epidemic periods, paired with
detailed analysis of recent impacts of RVF in South Africa and informed by a willingness-to-pay
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survey on RVF vaccination to identify barriers and enablers of prevention and control measures at
local level through the following three aims and primary hypotheses:
Aim 1: Compile and map global human and animal disease burden (cases, deaths, and incidence)
of RVF from 2000-2018, assessing correlation with country wealth, health system
capacity, and environmental and agricultural factors.
H1: RVF disproportionately causes disease burden in countries that are least-developed,
relative to countries that are most most-developed.
Aim 2: Characterize and estimate the multi-sectoral direct and indirect economic impacts
associated with Rift Valley Fever costs and losses in South Africa from 2000-2018 and
analyze the cost drivers in terms of their type, magnitude, and distribution.
H2a: Economic impacts of RVF disproportionately affect non-health sectors compared to
health sectors.
H2b: Costs are primarily allocated to response versus prevention activities.
Aim 3: Determine willingness to pay (WTP) and barriers and enablers for RVF prevention by
farms in South Africa’s Free State and Northern Cape provinces.
H3: WTP increases as perceived risk rises.
Understanding the types, distribution and magnitude of impacts associated with zoonoses such as
RVF can make their effects more tangible and guide investments in prevention and control to
maximize societal benefits. While global analyses suggest high return on investment from
prevention of epidemics versus reactive control,47,50 varied disease transmission patterns and
economic structures among countries requires more detailed analysis for country and sector-level
policy making. Analysis of anticipated RVF costs and prevention and control options for South
Africa can inform decisions under the National One Health Forum and national action plan for
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health security, including around ecological, animal and human risk monitoring as well as vaccine
production, distribution and pricing practices.

Overview of Methodology
Data was compiled from three different scales (global, national, and farm-level) corresponding
to each aim to understand the types and extent of recent impacts of RVF. Historical impacts have
been covered in previous publications; we restricted our focus to within the past two decades for
improved data validity and relevance to current prevention and control priorities and options. For
Aim 1, we quantified global impacts using official and unofficial reports of human and animal
disease and deaths from RVF, assessing bivariate correlation between RVF reporting and broad
country-level predictor variables for African nations and describing country development
characteristics as well as reviewing major capacity and implementation gaps. For Aim 2, we
conducted the first national cost analysis for RVF in South Africa, compiling available information
from prior scientific and grey literature and stakeholder groups to combine data from multiple
sectors (agriculture, health, environment, tourism, and finance) and identify the type, magnitude,
and distribution of expenditures and losses in outbreaks and inter-epidemic periods between 20032018. For Aim 3, we analyzed data from a farm-level survey on RVF prevention and control
practices and willingness to pay in South Africa’s Free State and Northern Cape provinces.
Specific methods are detailed in the subsequent chapters.

Conclusions
There are fundamental unanswered questions about the maintenance and transmission of RVF that
hinder precise predictability of future risk of outbreaks and spread. Therefore, consideration of
ways to optimize prevention and control using existing strategies is critically needed as a stopgap
to reduce impact, concurrent with research efforts for improved understanding of the basis ecology,
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epidemiology and pathogenesis of the disease. This dissertation takes stock of broad trends (see
paper 1) to consider their effects in the future and identify options for risk mitigation. The existing
research base has highlighted various important facets of RVF epidemiology, ecology, virology,
and socio-economic dynamics, but their links are rarely, and often incompletely, drawn.
Considering them in tandem is timely and crucial in the advent of the Sustainable Development
Goals and represents an opportunity for the public health sector to better emphasize upstream
prevention of disease risk and impact. Finally, this work advances understanding about the impacts
of RVF at different scales, identifies key knowledge gaps, and provides worked examples on how
information from multiple disciplines and sectors can be integrated in pragmatic ways intended to
inform multisectoral decision making for zoonoses and other critical issues with human, animal,
environment and socio-economic links. We believe this work provides a path forward for
operationalizing and generating tangible value from One Health and Planetary Health approaches
at the science-policy interface.
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CHAPTER 2 – SUMMARIZING HUMAN AND
ANIMAL HEALTH IMPACTS (AIM 1)
Abstract
Background: Rift Valley Fever (RVF) has caused major livestock outbreaks with zoonotic
spillover and economic consequences since its first detection in 1931. Understanding current
distribution and impacts of RVF can help target potential interventions to populations most
affected by the disease.
Methods: We quantified global impacts using official and unofficial reports of human and animal
disease and deaths from RVF between 2000-2019, assessing univariate correlation between RVF
reporting and broad country-level predictor variables for African nations and describing country
development characteristics. We also review major factors affecting the trajectory of RVF
globally.
Results: Between 2000-2019, a total of 5,228 suspected human cases and 987 deaths, as well as
72,960 animal cases and 17,810 deaths, were officially reported. Reports occurred in 32 countries
in Africa and the Middle East, with 22 countries reporting both human and animal cases. Higher
number of RVF publications was significantly associated with higher odds of official reporting of
RVF in Africa (OR=1.5), whereas higher level of political stability and absence of violence was
associated with lower odds of RVF reporting (OR=.39), as was higher percentage of population
with access to electricity (OR=.97) (all p<.05). On average, countries reporting RVF in Africa
have high dependence on livestock, and face major economic, infrastructure, and capacity deficits,
which can be expected to affect implementation and efficacy of RVF prevention, detection and
response efforts.
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Conclusions: To our knowledge, our analysis is the first to review human and animal disease
burden for RVF together. Given its multisectoral implications, a One Health approach is critical
for improving understanding of the impacts of the disease. Our findings highlight several gaps in
reporting and can inform policy considerations that can be used in design of vaccination and other
RVF prevention and control strategies to better reach vulnerable populations.

Introduction
Rift Valley Fever (RVF) is a zoonotic and vector-borne viral disease. Since its first detection in
1931, small and large-scale outbreaks in livestock and humans have periodically been reported in
Sub-Saharan Africa and the Middle East, with major events typically seen after anomalous rainfall
events or through introduction via livestock trade.1 Significant animal losses have been observed
in major epidemics. Although human-human transmission has not been documented, and most
infections present as mild, influenza-like illnesses, approximately 1% of patients experience severe
cases which may progress to retinal lesions potentially resulting in vision loss, as well as
meningoencephalitis and viral hemorrhagic fever, which may be fatal. RVF infections in humans
occur most typically via contact with infected animals or their fluids (e.g. blood, placenta), and
more rarely, via the bite of an infected mosquito. Screening for RVF can be done via several
diagnostic methods (which a given laboratory may or may not have access to). Common tests
include molecular screening techniques such as reverse-transcription polymerase chain reaction
(PCR), viral isolation from blood or tissue for active infections, or antibody testing (IgM, IgG) for
evidence of prior exposure. There is no known treatment for RVF aside from supportive therapy.
The disease remains an ongoing threat for sporadic epidemics, imposing major economic losses
for certain segments of the population, particularly those with high dependency on animal
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production and trade livelihoods.2 In addition, there is risk of potential introduction in
immunologically-naïve areas with suitable ecological niche for vector establishment, including
parts of North and South America.3,4
While RVF outbreaks are largely addressed separately by human and animal health sectors,
the disease exemplifies the need for an integrated One Health approach to disease prevention,
detection and response given the role of mosquitoes, livestock, and in some cases wildlife in its
maintenance and transmission, climactic and ecosystem variables affecting vector survival,
occupational risk factors facilitating disease spillover to humans, classification as a potential
bioterrorism agent, and the economic viability of different risk reduction strategies.5,6 Mitigating
RVF’s risks and impacts align with several Sustainable Development Goals (SDGs), including
poverty eradication for populations dependent on livestock rearing for income and financial
stability (SDG1), nutrition and food security access (SDG2), healthy populations and health
security (SDG3), sustainable use and protection of ecosystems and biodiversity (SDG15), climate
action through more efficient livestock production and greater preparedness for climate-sensitive
disease risks (SDG13), strong institutions able to support populations in managing RVF risks
(SDG16), and, crucially, partnerships bridging knowledge and implementation gaps across sectors
(SDG17).
While livestock vaccines are available for RVF, uptake is generally low, and no vaccine is
currently licensed for human use.7 The inclusion of RVF on the World Health Organization
(WHO) R&D Blueprint priorities for disease countermeasures in emergency contexts, along with
the Coalition for Epidemic Preparedness Innovations (CEPI) and EU Horizon 2020 program’s
mobilization of more than US$20 million in 2019 to advance two human RVF vaccine candidates
(RVFV-4 and DDVax), are welcome developments for global preparedness against RVF.8-10 To
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ensure future technology serves the needs of often vulnerable, low-resource populations at highest
risk of incurring greatest relative impacts, and to improve delivery of existing surveillance and
control measures, it is crucial to understand where current burden is centered and the socioeconomic determinants that may contribute to impact. This information can help target coordinated
strategies to overcome RVF as a neglected human and animal health threat.

Methods
We describe the distribution and burden (cases and deaths) of human and animal disease associated
with reported RVF outbreaks and assess correlation with hypothesized country-level predictor
variables.
Data sources and compilation
RVF is not among the diseases tracked annually via WHO’s Global Health Observatory, and
emergency notifications reporting of RVF outbreaks in humans are inconsistent and often do not
reflect the conclusion of events with final counts. To our knowledge, cumulative human cases of
illness and deaths from RVF have not been previously estimated. We compiled a database of
human cases and deaths from 2000-2019 using report and event summaries reported by the WHO
health emergencies program and regional offices (AFRO, EMRO), GLEWS (the Joint
FAO/OIE/WHO Global Early Warning System), World Organisation for Animal Health (OIE),
and ProMED. We manually reconciled information across reports, using additional information
from peer-reviewed papers where available, e.g. epidemic curves by month to determine primary
year of outbreak occurrence. As many reporting countries have limited diagnostic capacity and
number of laboratory-confirmed cases was rarely specified, we assumed that suspected cases and
deaths likely met the clinical case definition and could be assumed to be RVF with high certainty
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as RVF likely would be not considered in differential diagnoses in the absence of conditions
favorable for the disease.
In animals, infection with RVF is an internationally notifiable disease to the OIE. The 6monthly or annual reports are the internationally-accepted standard for reporting on OIE-Listed
Diseases, with information submitted directly from countries. Data was sourced from OIE
HANDISTATUS reports (2000-2004) and the World Animal Health Information System
(WAHIS) Portal (2005-2019). Reports for 2019 were only partially available at the time of data
collection (as of February 6, 2020).
To estimate disease impact, we targeted reported cases of illness and deaths, assuming these
reflected poor health status, rather than serological evidence of virus exposure alone as the latter
would produce case counts magnitudes higher but not necessarily be indicative of disease
burden.11,12 We reported on countries where >1 outbreak, case or death (animal or human) or
disease presence was reported, excluding countries indicating suspicion of infection with RVF
without outbreak or case listings. While prior studies have reported on cases of RVF, they have
mainly focused on major outbreaks (for an overview of historical RVF distribution including pre2000 information, please see previous reviews).13
Analysis
We compiled an Excel database with animals and human cases and deaths by country and year.
Summary statistics were conducted in STATA/IC version 16.0. Maps of animal and human cases
reported by country for 2000-2019 (via OIE, WHO and ProMED) and geo-located RVF event data
available for 2006-2019 via the Global Early Warning System (GLEWS) overlaid with reported
insecticide resistance via VectorBase (all mosquito species, 1985-2019) were generated in R using
the ‘rworldmap’ package and in QGIS version 3.4.15.
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Environmental and occupational risk factors have been reported for RVF in prior studies.14-17 To
complement this existing area of research, we examined the relationship between reporting of
RVF and country-level variables reflective of economic development, production, workforce,
and disease trends potentially indicative of vulnerability to RVF impacts and important for
uptake of vaccine and other interventions: number of veterinarians (count), access to electricity
(percentage), portion protein from animal sources (percentage), stability (aggregate indicator in
units of a normal standard distribution), Gini coefficient (a wealth distribution measure between
0 and 1, with 0 being perfect equality), gross national income (GNI) per capita (US$), number of
sheep and goats (an aggregate to two variables, as livestock units), number of cattle (livestock
units), health expenditure per capita (US$), gross domestic product (GDP) share from
agriculture, fisheries, and forestry (percentage); malaria incidence per 1,000 at risk (count); and
number of RVF publications (count) (see Table 1.1). Country variables were sourced from highquality reporting sources (e.g. World Bank, UN agencies) and selected on the basis of reporting
completeness for African nations as well as plausibility as predictor variables, having a viable
role in RVF susceptibility and management (e.g. via implications for protein or nutrition
reliance, livelihoods, infrastructure for vaccine cold storage) but likely too broad to be directly
causal (particularly given variation at sub-national level not reflected in overall country
indicators). Country variables were averaged for available years between 2000-2019 (for
malaria, the interval of reporting changed during the time frame, and thus we calculated the
average of 2000, 2005, 2010, and 2015 data). Univariate logistic regression (countries reporting
versus not reporting) was performed in STATA to detect differences in countries reporting and
not reporting RVF (i.e., 1 and 0).
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In light of under-reporting to official sources, we also reviewed scientific publications for
published estimates. We used these estimates to calculate a scaling factor for animal and human
cases and deaths, multiplying officially reported numbers to provide a minimum and upscaled
range.

Results
Case and death burden- official reporting
Between 2000-2019, there were 5,228 suspected human cases and 987 deaths recorded from RVF
via WHO, OIE, and ProMED, plus a total of 72,960 animal cases of RVF officially reported to the
OIE, associated with 17,810 animal deaths and 183 animal destructions (i.e. herd culling for
disease control) (Figure 1). In comparison, the FAO/OIE/WHO Global Early Warning System
(GLEWS) reported only 29,048 animal cases, 13,794 animal deaths, and 747 human cases, and 89
human deaths between 2006-2019 (the years available).
Animal disease reporting to OIE also indicated 1,275 outbreaks (outbreaks are typically
defined as unique by farm or site) during the time period; however, many reports lacked outbreak
counts. Additional confirmed or suspected infection or disease during the time period was reported
to the OIE without case or outbreak numbers, indicating true counts are likely higher. For animal
disease events reported, 4,862,704 animals were identified as susceptible. The majority of animal
cases occurred in sheep, cattle, and goats, respectively, with death highest among sheep (Table 1.2
and Figure A1.1).
Countries reporting RVF
Of the 71 member states in the Middle East and Norther Africa and Sub-Saharan Africa regions,
RVF was reported in 32 countries between 2000-2019 (see Table A1.2). Twenty-two countries
reported evidence of RVF in both animal and humans (see Figure 1). More detailed location
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information was available for 2006-2019 via the Global Early Warning System (GLEWS). We
overlaid RVF event reports in GLEWS with reported insecticide resistance (all mosquito species,
1985-2019) (Figure 2).
Reporting by year
Trends in human and animal cases and deaths by year from official sources are shown in Figures
3a-b. For some multi-year outbreaks in humans, information about the distribution by year was
not available. While some years saw concurrent animal and human outbreaks reported, these
associations were less pronounced in certain years (e.g. 2000, 2010, 2014).
Scaling for under-reporting
The definition for an RVF case is not always consistent or complete. In their review of five major
outbreaks between 1997-2010, Dar et al. estimated that human infections totaled ~339,000,
representing 78 times reported cases.18 However, some surveillance reports have shown high
seroprevalence without reported disease in animals (e.g. Somalia). Based on review of select
examples (Table 1.3), we find high discrepancy between official and unofficial case and/or death
reports for animals and humans. These reinforce likely under-reporting in some cases and may
help consider additional source of disease burden unaccounted for (e.g. differential diagnoses of
febrile illness during prolonged periods of rainfall and associated cause of abortions) that could
help target areas for enhanced surveillance and resources.
Country indicators and predictors of RVF reporting
Summary statistics on development indicators for countries reporting RVF are shown in Table
1.4 for the years 2000-2019 and the odds of official reporting of RVF for each unit increase of
these indicators is shown in Table 1.5. Of twelve country-level predictor variables, higher
number of RVF publications was significantly associated with higher reporting (OR=1.6),
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whereas higher level of political stability was protective against RVF reporting (OR=.39), as was
higher percentage of population with access to electricity (OR=.97) (all p<.05).
Impacts of RVF
Examples of multi-sectoral impacts of RVF are shown in Figure 4. These are wide-ranging, from
threats to nutrition and food security, trade and GDP losses, morbidity and mortality in humans,
livestock and wildlife, and psychosocial impacts affecting quality of life.19 High financial
dependence on livestock in Somalia, where taxation of livestock exports generates the majority
of government revenue, shows the extent of some countries’ vulnerability to RVF beyond its
public health implications.

Discussion
We summarize RVF disease reports for animals and humans from the past 20 years. Our findings
demonstrate that RVF is a widespread threat in the African continent over the past 20 years, while
also indicating a high potential extent of underreporting that hinders full understanding of potential
animal and human disease associations and burden estimates. Future studies may wish to look
more precisely at development indicators, potentially across sub-regions where the environmental
conditions for RVF risk may be similar but infrastructure, income and other development variables
may vary widely by country or urban versus rural access to services. For our model assessing RVF
reporting by countries and development indicators, since stability and electricity access are likely
to be positively correlated, running the logistic regression with the three significant factors in one
model could help identify which is strongest in the presence of the other. As development
indicators may change substantially over time, potentially weakening in times of conflict or
alternately strengthening through major infrastructure investment, a shorter temporal interval
would be more precise than averages over the 20-year period. We discuss the wider implications
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of our findings below, identifying a range of factors influencing changes for RVF risk and impact
globally where several disciplines can contribute to advancing research and policy to counter RVF.
Reporting
Our findings show inconsistencies across reporting sources. In addition, at least one country with
prominent outbreaks (Somalia) did not officially report to the OIE, reinforcing that reporting relies
on good governance and functional veterinary services. The significant association between
countries reporting RVF and number of RVF publications lends further weight to the possibility
that human or animal cases may be going undetected in the absence of surveillance programs.
Research bias has been reported in prior studies on predictors of zoonotic and other emerging
infectious diseases and viral host species (Jones et al.; Allen et al; Olival et al).20-22 While we
focused on clinical cases, serological studies have detected RVF incidentally in additional
countries (e.g. in Gabon, cross-sectional studies found

seroprevalence of 3.30% in rural

populations and 6.47% in sheep and goats tested).23,24
Human and animal case and deaths counts were based on data extraction from official sources.
However, in the absence of an high-validity international systematic surveillance and reporting
system for RVF, informal data sources, including research publications, can be helpful for
examining wider burden and targeting attention to areas of needed for greater screening and disease
management efforts. This may be particularly valuable given that RVF may not be on a country’s
standard public health or animal health reporting list. In some cases, there may be real disincentives
to national authorities screening for RVF given its importance as an agricultural disease, resulting
in suspected outbreaks going uninvestigated out of fear of possible trade implications. One major
challenge based on under-reporting is the use of official sources of data alone as a basis for policy
and investment decisions, when this information may leave out critical on portions of the
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population affected by RVF but without access to testing services. In these cases, inference from
even small-sale exploratory research studies, such as one that has examined prevalence of RVF in
malaria-like illnesses following periods of heavy rainfall, may help to extrapolate potential burden
in other communities or country to more fully account for burden. For all of these reasons, informal
data sources add an additional layer of information to assess need and target resources. At the same
time, informal sources may not be standardized across studies, particularly in distinguishing
evidence of infection (i.e., antibody detection) from clinically-relevant illness, which may make
data comparability challenging.
Diagnosis challenges
While severe cases may have unique pathologies (e.g. ocular disorders), the non-specific clinical
manifestations in both animals and humans, especially for typical, mild cases, makes detection and
confirmation challenging (Table 1.6). These detection factors are thought to be particularly
pronounced in areas with low awareness of RVF and/or limited surveillance and diagnostic
capacity. A major impediment is that clinical testing is poorly available, reported as mainly limited
to international reference laboratories.25
Impacts Outside of Africa and Middle East
Between 1979-2018, eight countries outside of the African continent and the Middle East (Sweden,
Canada, the Netherlands, France, Germany, the United Kingdom, China, and the Republic of
Korea) experienced a total of 17 imported human cases (GIDEON). Several studies have also
considered viable transcontinental transmission routes into Europe and the U.S., including via
viremic hosts (livestock, wildlife, and humans), vectors, and bioterrorism scenarios and potential
impact of widescale introduction events.3,13,26 The potential susceptibility of immunologically
naïve animals has been identified as a potential factor that could facilitate rapid spread in livestock
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and potentially impact populations of endangered species (such as bighorn sheep in North
America).3
Human Impact
As person-person transmission of RVF has not been documented, reported cases indicate at least
5,228 unique spillover events from animals or mosquitoes to humans in the past 20 years alone.
Aside from dedicated serosurveys, evidence of RVF or RVFv in humans is typically reported only
when people seek medical services when clinical signs appear or in response to fatalities (i.e.,
symptomatic patients); however, cases may be missed in mild, non-specific, or misdiagnosed
infections or in those who do not or cannot seek care (e.g. financial or physical access, mistrust of
the formal healthcare system, etc.). Dar et al. (2013) estimated cases from five major RVF
outbreaks occurring between 1997-2010 as approximately 339,000, far exceeding officially
reported counts.18
Animal Impact
RVF outbreaks in animals have been associated with large-scale economic losses. RVF should be
considered in the larger context of climate- and disease-smart livestock rearing, including
cultivation of breeds suitable to local conditions, which should be prioritized by development
donors, technical agencies, and national governments to address current threats and mitigate
against those on the horizon.27 Overall, approximately 20% of annual animal production at present
is lost due to disease, equivalent to 60 million tons of meat and 150 tons of milk.27,28 Improved
animal disease prevention and control may confer efficiencies and benefits for production,
nutrition, and animal welfare, while limiting negative externalities (e.g. climate emissions,
deforestation for livestock grazing, intensive water resource use). These outcomes are not
insignificant in the context of meeting projected increased animal protein demands.

24

Environmental considerations
RVF is known to be climate-sensitive, yet the potential effects of climate change are poorly
understood for RVF and other vector-borne diseases, particularly in Sub-Saharan Africa.29
Although risk prediction using forecasting models is becoming more precise, to date prevention
at source is insufficiently built into public and animal health planning and implementation on the
ground. To widen the network of reporting inputs and facilitate early detection and risk
reduction, several participatory community surveillance programs have been piloted for RVF in
several countries, including with nomadic pastoralists in a remote region of Nigeria.30,31
Prior work suggests major deficits in knowledge of RVF and its specific symptoms, where
veterinary and public health services could provide supportive risk communication and
awareness interventions as part of livestock husbandry and risk communication efforts. Overall,
the African continent has limited capacity for zoonotic disease response (Figure 5), leaving
populations vulnerable to disease outbreaks when they do occur. Collectively, these
environmental, capacity, and other factors have implications for risks and impacts in the region
and globally that should be considered in the design of multisectoral strategies to counter RVF
(Table 1.7).
Conclusion
Given its multisectoral impacts, RVF should be considered in the overall risk profile for
susceptibility to emergencies, such as disease but also drought, flood, theft, and predation, in
countries with agricultural communities highly dependent on livestock for nutrition or livelihoods.
For example, agricultural communities in East and Southern Africa have suffered recent multiyear droughts, locust invasions, and other diseases (e.g. Brucellosis) in addition to RVF. Improving
coordination between human and animal reporting authorities to more comprehensively and
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systematically capture impacts will help to promote One Health coordination on the ground and
inform intervention strategies.
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Table 1.1 National indicators hypothesized to affect RVF distribution.
Indicator

Variable

Available
Years
Demography, economy, and stability indicators
1
Sheep and Goats
2000-2016

Metric

Source

Relevance

Livestock units (LU)

FAO
STAT

2

Cattle

2000-2016

Livestock units (LU)

FAO
STAT

3

Agriculture, forestry,
and fishing, value
added (% of GDP)

1960-2018

% of GDP

World
Bank

4

Political Stability and
Absence of
Violence/Terrorism

2000, 20022015

Aggregate indicator in
units of a normal
standard distribution (~ 2.5-2.5)

World
Bank

5

2000-2018

Numeric

World
Bank

6

Gross National
Income per capita,
Atlas method (US$)
GINI coefficient

Livestock
production
extent
Livestock
production
extent
Economic
dependency on
agriculture (no
livestockdisaggregated
indicator)
Likelihood of
political
instability
and/or
politicallymotivated
violence
Country
income

Sporadic

0-1 (0=perfect equality)

7

Access to electricity

2000-2018

% of population

World
Bank
World
Bank

Wealth
distribution
Cold chain
infrastructure

OIE
WAHIS

Animal health
workforce
capacity

World
Bank

Human health
system
investment

Animal and human health workforce and system indicators
8
Number of
2005-2017
Numeric count
veterinarians and
veterinary paraprofessionals
9
Per capita health
2000-2016
US$ per person
expenditure
Nutrition and food security indicators
10
Protein supply from
animals/total protein
supply
Disease Detection and Outcomes
11
Malaria incidence

Other
12

Publication bias

1999-2013
(1999-01,
2000-02...)

gr/caput/da
(proportion from two
FAO datasets)

FAO

Reliance on
animal-source
protein

2010-2017,
2005, 2000

Incidence per 1,000
population at risk

WHO

Vector-borne
disease
detection

1968-2016

Number (total) of RVFV
seroprevalence studies,
by African country

Clark et
al. 2018
PLoS
NTD

Surveillance
effort
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Table 1.2 Animal cases and deaths by species from RVF reported to OIE, 2000-2019.
Species
Cases
Deaths
Destroyed
Cattle
21,413
2,565
40
Goat
17,448
2,651
26
Sheep
24,579
11,257
103
Sheep/Goat
8,588
741
2
Camel
710
142
12
Wildlife*
113
93
0
Unknown
109
26
0
Total
72,960
17,810
183
*wildlife includes buffalo, rabbit, and other non-specified fauna.

Figure 1.1 Map of official reports
in animals, humans, or both, 20002019.

Figure 1.2 Geo-referenced RVF animal and human events
(green) and reports of insecticide resistance (green). Data
sources: GLEWS Early Warning System and VectorBase.
Points off mainland Africa represent Indian Ocean islands.
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Figure 1.3a-b. 1.3a) Human cases and deaths by year, annual and cumulative, and 1.3b) Animal
cases and deaths by year, annual and cumulative.
a. Cases and Deaths from RVF by Year, 2000-2019 (Humans)

Number of people

6,000
5,000
4,000
3,000

2,000
1,000
0
Cases

Year

Cumulative Cases

Deaths
Cumulative deaths

b. Cases and Deaths from RVF, 2000-2019 (Animals)
80,000
70,000
60,000

Number of animals

50,000
40,000
30,000
20,000

10,000
0

Year
Cases

Deaths

Cumulative Cases

Cumulative deaths
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Table 1.3 Examples of case and deaths reported in formal vs. unofficial sources.
Location

Scope

Timeframe

Formally
Reported

Other
Estimate

Source

Case
Ratio

Animal
Yemen

Outbreak period

20002001

2,408 cases;
659 deaths
(2001-2007)

Admad 2000

1:9
(deaths)

Bans on exports on
suspicion of RVF
Eastern Cape, Northern
Cape, Free State

20002004
20082011

Not reported

21,000 animal
abortions;
6,000 animal
deaths
2-80% seroprevalence
Reduction of
400,000 sheep

Soumare et al.
2006
Mdlulwa et al.
2015 and 2017

N/A

Outbreak period

20062007

1,062 cases,
315 deaths

145,000 cases

Anyamba et al.
2010

1:136

Outbreak period

20072009
2013

712 cases,
26 deaths
N/A

10,000 cases
(2007-2008)
5% (10/200)

Anyamba et al.
2010
Gudo et al. 2016

1:14

20102011

213

3,849

1:18

20072008
20112012

747 cases,
230 deaths
Not reported

75,000

Archer et al.
2013; Msimang
et al. 2019
Anyamba et al.
2010
Baudin et al.
2016

Somalia
South Africa
Human
Kenya,
Somalia,
Tanzania
Madagascar
Mozambique

South Africa

Acute febrile illness
during heavy rainfall
and flooding (including
malaria misdiagnoses)
Free State and Northern
Cape

Sudan

Outbreak period

Sudan

Pregnant women with
febrile disease

17,611
animals

28/130;
miscarriages in
54% of cases

1:23

N/A

1:100
N/A

Table 1.4 Development indicators for countries reporting RVF in animals, humans, or both, 20002019.
Variable
Number of veterinarians
Access to electricity
Portion protein from animal sources
Stability
Gini Coefficient
GNI per capita
Number of sheep and goats
Number of Cattle
Health Expenditure Per Capita
GDP Share from Agriculture, Fisheries, Forestry
Malaria incidence*
Number of RVF Publications
*Average of 2000, 2005, 2010, and 2015

Unit
Count
%
%
Scale (~-2.5-2.5)
Scale (0-1)
US$
Animals
Animals
US$
%
Per 1,000 at risk
Count

Mean
3,919.93
32.12
.29
-.85
43.99
1,364.62
1,490,484
4,312,950
82.51
22.73
188.78
5.17

Range
12 - 45,324.14
5.61- 99.18
.12 - .47
-2.82 - .99
30.64 - 62.40
199.47 - 5714.74
14,118.66 – 8,428,337.00
24,938.66 - 2.41e+07
13.26 - 394.29
2.35 - 46.75
0 - 432.60
0 – 48
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Table 1.5 Univariate analysis. Reflects averages over available years unless specified.
Variable
Number of veterinarians
Access to electricity
Portion protein from animal sources
Stability
Gini Coefficient
GNI per capita
Number of sheep and goats
Number of Cattle
Per Capita Healthcare Expenditure
Share of GDP from Agriculture,
Fisheries, Forestry
Malaria incidence*
Number of RVF Publications
*Average of 2000, 2005, 2010, and 2015

1.000092
.9715416
7.556949
.3952256
1.045787
.9997167
1
1
.9973592
1.025616

Standard
Error
.0000888
.0109338
20.85614
.1541593
.0433473
.0001466
1.89e-07
1.93e-07
.0026868
.0212051

.9978721
1.566757

.0018628
.2849671

OR

0.299
0.010
0.464
0.017
0.280
0.053
0.211
0.010
0.326
0.221

95% Confidence
Intervals
.9999182 - 1.000266
.9503463 - .9932096
.033818 - 1688.672
.1840054 - .8489061
.9641873 - 1.134293
.9994293 - 1.000004
.9999999 - 1.000001
1 - 1.000001
.9921071 - 1.002639
.9848857 - 1.068031

0.254
0.014

.9942277 - 1.00153
1.096938 - 2.237799

P>|z|

Figure 1.4 Examples of impacts of RVF.
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Table 1.6 Differential diagnoses for RVF for animals and humans.
Population Other Diseases with Similar Clinical Signs
Animal
bluetongue, Wesselsbron disease, enterotoxemia of sheep, ephemeral fever, brucellosis,
vibriosis, trichomonosis, Nairobi sheep disease, heartwater, ovine enzootic abortion, toxic
plants, bacterial septicaemias, peste des petits ruminants, anthrax and Schmallenberg
disease
Human
malaria, rickettsial infections, Q fever, typhoid fever, dysentery, plague, brucellosis,
leptospirosis, meningitis, other sepsis from bacterial infections, viral hepatitis, other viral
haemorrhagic fevers, non-infectious causes of disseminated intravascular coagulopathy,
and acute leukaemia
Sources: Animal: OIE Terrestrial Manual 2018. Human: Paweska J.T. & Jansen van Vuren P. (2013). −
Rift Valley fever virus: a virus with potential for global emergence. In The role of animals in emerging
viral diseases (N. Johnson, ed.). Elsevier Academic Press, Waltham, Massachusetts, 169–200, and
Paweska 2015. OIE Sci Tech Rev.

Figure 1.5 Map displaying scores for zoonotic disease response mechanisms in African nations assessed
via the WHO Joint External Evaluation (1=lowest capacity; 5=highest capacity; white=no data). None
received a score of 5. Data extracted from JEE mission reports (WHO website; reflects reports posted as
of November 2019).
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Table 1.7 Major factors influencing changes (positive or negative) for RVF risk and impact globally.

Change
Viral evolution

Weaponization

Environmental:
climate change,
ecosystem
degradation,
biodiversity loss
and invasive
species
introductions

Broad trajectory for change
• Viral evolution, including reassortment between circulating
and vaccine-attenuated strains,
leading to change in
virulence32,33
• Bioterrorism (dissemination of
virus with no known
countermeasures)34
• More frequent extreme weather
events
• Increased mean temperature
• Vector habitat change (water,
vegetation, soil, host
dependencies)- effect of
desertification and drought in
some areas
• Livestock, wildlife and human
migration
• Increased speed and volume of
trade and travel (especially
international and
intercontinental)

Possible outcome(s) for RVF
• Change in severity of cases
• Change in potential for spread in
healthcare settings
• Change in mosquito-human
transmission
• Change in pathogen exposure
•
•
•
•
•
•
•
•

•
Livestock
production

•
•
•

Technology
•
development/
countermeasures •
•
•
•

Livestock density
Production practices and
occupational safeguards
Trading practices (e.g.
regulations and sanctions)
Medical countermeasures (e.g.
antivirals)
Human vaccine
Multivalent vaccine
Storage requirements
Ecosystem-based integrated
pest management

•
•
•
•
•
•
•

Change in mosquito range
Change in mosquito hatching
years and events per season
Change in mosquito succession
patterns
Change in exposure to RVF
vectors
Change in mosquito and/or virus
survival
Change in vector distribution
Change in insect control measures
Change in pathogen exposure,
potentially in immunologically
naïve human, animal or vector
population
Change in vector species
composition
Change in introduction and
movement of infected animals
Change in exposure frequency
and intensity
Change in infection duration and
potential severity
Change in human susceptibility
Change in uptake of livestock
vaccination (likely increased)
Change in efficacy and efficiency
of vaccine administration
Change in localized circulation of
vector and virus
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Syntax
STATA
*graphing by species*
graph box cases deaths, over(species)
*univariate analysis for RVF reported (1) and not reported (0): logistic regression*
logistic RVFany AVE_Vets_AllYears
logistic RVFany AVE_Electricity_AllYears
logistic RVFany AVE_PercentAnProtein_AllYears
logistic RVFany AVE_Stability_AllYears
logistic RVFany AVE_GI_AllYears
logistic RVFany AVE_GNI_AllYears
logistic RVFany AVE_SheepGoats
logistic RVFany AVE_Cattle
logistic RVFany AVE_HealthSpend
logistic RVFany AVE_AgGDP
logistic RVFany AVE_Malaria
logistic RVFany Publicationspercountry
*summary statistics for RVF reported (1)*
summarize AVE_Vets_AllYears if RVFany==1
summarize AVE_Electricity_AllYears if RVFany==1
summarize AVE_PercentAnProtein_AllYears if RVFany==1
summarize AVE_Stability_AllYears if RVFany==1
summarize AVE_GI_AllYears if RVFany==1
summarize AVE_GNI_AllYears if RVFany==1
summarize AVE_SheepGoats if RVFany==1
summarize AVE_Cattle if RVFany==1
summarize AVE_HealthSpend if RVFany==1
summarize AVE_AgGDP if RVFany==1
summarize AVE_Malaria if RVFany==1
summarize Publicationspercountry if RVFany==1

R (Maps)
*Joint External Evaluation scores, Africa*
# Make map of countries
library(rworldmap)
library(ggplot2)
map.world <- map_data(map="world")
setwd("/Users/CatherineMachalaba/Dropbox (EHA)")
# load data
data <- read.csv(file = "JEE_Africa_v2.csv", strip.white = TRUE)
head(data)
# colors <- as.vector(unique(data$color))
colors <- c("red", "orange", "yellow", "green")
#mapDevice('x11')
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#join to a coarse resolution map
dataMap <- joinCountryData2Map(data, joinCode="ISO3", nameJoinColumn="ISO3")
#write pdf
#pdf("m.pdf", width=11, height=8.5)
m <- mapCountryData(dataMap,
nameColumnToPlot="Score",
catMethod="categorical",
addLegend=F,
colourPalette = colors,
oceanCol = "aliceblue",
mapTitle = "",
borderCol=gray(0.2),
missingCountryCol = "#ffffff",
mapRegion = "Africa")
#m$legendText <- c('NA','Past','Current')
do.call( addMapLegendBoxes, c(m,x='bottomleft', title="Score",horiz=F))
#dev.off()
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CHAPTER 3 – ONE HEALTH COST ANALYSIS:
RVF IN SOUTH AFRICA (AIM 2)
Abstract
Background: Previous outbreaks of Rift Valley fever in Africa and the Middle East have been
associated with human and animal health impacts and significant economic losses. While RVF
epidemics have occurred in South Africa in recent decades, the economic implications for the
country beyond partial losses to the livestock sector have not been characterized to date.
Methods: We conducted a multi-sectoral cost analysis of expenditures and losses associated
with Rift Valley Fever in South Africa between 2003-2018 using health sector and societal
reference perspectives. Cost identification for expenditures and losses was obtained via literature
review and stakeholder consultation to generate totals by year and sector. We used one-way and
multivariable sensitivity analyses to vary cost items where there was high uncertainty. We
classified the type, magnitude, and relative distribution of impacts for different sectors to analyze
outbreaks and in inter-epidemic periods.
Results: At least US$120,600,299 (2020 dollars) in spending and losses were attributable to
RVF between 2003-2018. The ratio of costs for prevention versus response was approximately
1.6 : 10.4. Impacts were concentrated during major epidemic periods. In the base scenario, 85%
of total costs were incurred in the livestock sector. The burden of disease for human cases was
estimated at 680.913 DALYs, with the majority from early death.
Conclusions: RVF has economic implications for a range of stakeholders and requires a societal
view to comprehensively account for impacts. Our findings offer a starting point for costeffectiveness analyses to identify options for optimal RVF prevention and control strategies in
South Africa.

38

Introduction
Recent outbreaks of emerging zoonotic diseases have resulted in high financial costs as a result of
intensive public health response, medical treatment, loss of human and material productivity,
quality of life impacts, trade and travel bans, agricultural losses, disruption of routine health and
education services, and more.1,2 Global analyses have extrapolated the potential cost savings of
greater investment in capacity to address zoonotic disease threats, as well as the cost of inaction.1,3
However, assessment of disease impact and cost-effective strategies for zoonoses control remains
limited at country context.
Rift Valley fever (RVF), a mosquito-borne viral zoonosis first detected in 1931 in Kenya, with
subsequent major outbreaks in East and Southern Africa, is thought to be enzootic in South Africa,
sporadically resulting in larger epidemics. Extending data reported by Pienaar et al. from 19502011 up to 2018, outbreaks were reported in 28 of 68 (41%) “seasons” (defined as years running
from July – June) in South Africa, including three major epidemics affecting large areas of the
country in 1950-1950, 1974-1976, and 2010-2011.4 Outbreaks have largely been concentrated in
central interior of South Africa. The last epidemic, between 2008-2011, resulted in major losses
and abortion storms in animals and 302 laboratory-confirmed human cases. Despite its severe
impacts on agricultural livelihoods, risks to human health, and associated economic consequences,
attention to RVF has largely been neglected and there is no national strategy for prevention and
control of the disease in South Africa.
Various impacts of Rift Valley Fever have been reported in prior studies. In addition to direct
losses, effects on international agricultural trade status may be significant; the cost to agricultural
supply from the 2006-2007 outbreak in Kenya was estimated at US$30 million.5 A previous review
identified high variability by country in proportional economic impacts of RVF to affected
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sectors.6 However, few studies have applied a ‘One Health’ lens integrating human, animal and
environment sector impacts. The potential utility of One Health economic analyses at country level
have been highlighted as a path to identify affected sectors and inform cost-effective coordinated
intervention and investment strategies against zoonoses, particularly for national budgeting
decisions.7,8 Only partial livestock sector costs of RVF have been estimated for South Africa.9 To
more comprehensively account for impacts, we developed a first national estimate of the
multisectoral costs of RVF in South Africa.

Methods
This study sought to identify the multi-sectoral economic impacts associated with Rift Valley
Fever in South Africa and analyze cost drivers in terms of their type, magnitude, and distribution.
A 15-year timeframe (2003-2018) was selected given the sporadic nature of RVF outbreaks. We
hypothesized that economic impacts of RVF disproportionately affect non-health sectors
compared to health sectors, and that costs are primarily allocated to response versus prevention
activities. Our analysis relied on secondary data from multiple sources at micro, meso, and
macro-economic levels:10 individuals or farms, industry (e.g., commodity associations), and
public sector entities (national or sub-national government).
Several methods have been proposed to account for human or animal diseases impacts, ranging
from micro-costing at household or farm level to national Social Accounting Matrices based on
economic transaction flows.11,12 Our cost identification was structured to provide the basis for
future cost-benefit analyses via stakeholder identification, understanding the distribution of
impacts, and practical budgeting decisions in the context of South Africa. We generally followed
guidance from the Second Panel on Cost-Effectiveness in Health and Medicine, which
recommends use of health sector and societal reference perspectives and a multi-sectoral impact
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inventory to account for consequences.12 As in previous studies conducting economic assessment
of RVF and other zoonotic diseases, our analysis reflected a partial equilibrium market model
under the theory that RVF is fundamentally a “public bad” for society; we did not consider possible
benefits from outbreaks and it was beyond the scope of this analysis to quantify downstream effects
on larger macro-economic systems such as market substitution.13
We conducted scientific and grey (e.g. government reports, farmers magazines, industry
websites) literature review in English and Afrikaans, institution- or industry-level stakeholder
consultation, and expert review from local researchers. This study did not involve human subjects
research and received IRB exemption from the City University of New York School of Public
Health and Health Policy. We excluded externally-funded research, assuming it was not indicative
of sustainable domestic investment to counter RVF. An impact inventory flowchart was generated
(Figure 2.1), based on theoretical impacts by sector based on the general distribution of authority
and/or commodity goods in South Africa. We defined costs as inclusive of expenditures associated
with RVF and losses from avoided revenue. We included both direct and indirect costs (direct
costs of disease are typically defined as medical costs incurred from disease, treatment, or control,
whereas indirect costs are non-medical costs, e.g. wages losses).
There were two RVF outbreaks during the period of study: a major epidemic affecting all
provinces between 2008-2011, and an isolated outbreak on one farm in 2018. In addition to
outbreak costs, we analyzed spending in inter-epidemic periods to examine investment in
prevention. Losses to livestock farmers in the 2008-2010 outbreak were previously estimated by
the Agriculture Research Council.9 Our study incorporates this prior work, estimating other cost
items incurred in the health, agriculture, environment, and tourism sectors for a multi-sectoral,
“One Health” cost analysis. Prior estimates could not be verified, but in general were considered
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high quality given that they were based on official data reported by the government, industry, or
are the accepted standard (e.g. disability weights). Other estimates were based on publiclyavailable or stakeholder data to generate best estimates.
Data were compiled and analyzed in Excel version 16.16.18. One-way and multivariable
sensitivity analyses were conducted to vary parameters where there was limited data availability
or high uncertainty. Cost analysis was conducted to break down impacts by cost driver, including
by sector, activity, payer, and public versus private expenditures.
Costs were adjusted for inflation using annual inflation rates and converted to 2020 dollars
(Table A2.1). Impacts were expressed as true costs; therefore, no discount rate was applied. Values
in Rand refer to original data inputs and cost item calculations. We used the latest currency
conversion value available (February 1, 2020) to standardize values to US$, at 14.75 South African
Rand to 1 USD (UN Treasury).

Results
The following sections detail estimated impacts by cost driver or payer sectors (health,
agriculture/livestock, environment, tourism, and finance) and in aggregate, based on theoretical
impacts (Figure 2.1). Identified costs represent a mix of expenditures and revenue losses (see
Table A2.2 for breakdown by type).
Health
We measured health sector impacts via: a) disease burden, b) healthcare and associated costs, c)
productivity loss from absenteeism, and d) public health services (e.g. outbreak
response/investigation).
a) Disease Burden

42

Disability-adjusted life years (DALYs) reflect years of productive life lost to disability or
mortality. We estimated DALYs attributable to RVF to inform cost of illness and productivity loss
estimates. The basic equation combines Years Life Lost (YLL) with Years Lived with Disability
(YLD):14
𝐷𝐴𝐿𝑌𝑠 = 𝑌𝐿𝐿 + 𝑌𝐿𝐷
RVF is not among the diseases systematically tracked by the Global Burden of Disease study and
no RVF burden estimate exists for South Africa. Several DALY calculations have been conducted
for the 2006/2007 outbreak in Kenya under varying parameters. For example, Orinde estimated
4,035.62 DALYs for 684 human cases and 155 deaths using age-disaggregated case data.15 An
alternate estimate indicated 3,974.05 total unweighted DALYs in high-risk populations based on
9,250 estimated acute cases and 90 deaths under the assumption that 10.9% of cases experienced
severe chronic infections.16 LeBeaud et al. estimate 4-10% of RVF survivors experience severe
chronic outcomes. Select information was available for the 302 confirmed cases and resulting 25
case fatalities (Table 2.1).
To calculate YLL, we calculated years of premature mortality for the 25 deaths attributed to
RVF, all of which occurred in 2010.17 Mean age of death was 44 (cases ranged from age groups
10-19 to >=70) (Table 2.1). We used WHO Global Health Observatory life table data to determine
remaining life expectancy by age group in 2010 (see Table A2.3 and a comparison of methods in
the Appendix), averaging across 5-year increments to match available 10-year increment case
fatality information.18 As sex was not known, we used values for males based on the high ratio of
male:female cases (Table 2.1) and as these yielded more conservative values. We estimate there
were 628.65 years life lost among RVF fatalities. YLD was calculated as:
𝑌𝐿𝐷 = 𝐼 × 𝐼 × 𝐿, where
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I = incident number of cases
DW= disability weight
L= average duration of the case until remission or death (years)
Accounting for variation in severity and length of disease, we estimated 70% of confirmed cases
in 2008-2011 experienced a mild acute episode of infectious disease lasting one week, 25%
experience two weeks of moderate severity illness, and 5% experienced month-long severe
disease. Based on prior estimates of RVF burden,19 we estimated 4% (n=12) experienced chronic
disease outcomes, splitting these evenly between two conditions: ocular disorders manifesting into
severe vision impairment and severe motor impairment from neurological complications, each for
the remainder of their life. As we lacked detailed case sequalae information, we used the difference
between median age of cases (43)17 and life expectancy at birth for 2010 to estimate remaining
years of life for the 12 cases with permanent disability, i.e. 14.67 years each. Using disability
weights (see Table 2.2),20 we estimated the aggregate Years Lived with Disability (YLD) across
all conditions attributable to RVF. The full number of historical infections in part of South Africa’s
Free State and Northern Cape was ultimately estimated as 3,849 based on follow-up serological
testing, suggesting the national number is higher.21 Prior studies excluded asymptomatic cases
from DALY calculations.15,16 However, an estimated 80-90% of cases are thought to experience
influenza-like illness;21 we estimated 80% (2,777) experienced an episode of mild illness for 3
days.
For the 2018 outbreak, six people experienced a mild acute episode of infectious disease lasting
one week, based on epidemiological findings by the National Institute for Communicable Disease
(NICD).22 Outbreaks of RVF in other countries have been associated with a range of healthrelevant impacts, including food insecurity and psychosocial impacts via fear and loss of societal
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status.23,24 We assumed South Africa’s relatively high capacity for disease management and social
services (e.g. access to public hospitals and schools) would provide some resilience and therefore
did not believe these to be significant in the South African context. Therefore, we did not attempt
to estimate impacts on nutrition status or quality of life.
We estimate 680.912 DALYs attributable to the 2008-2011 RVF epidemic and .001 for the
minor 2018 outbreak (a total of 680.913 DALYs from 2003-2018). For comparison, South Africa’s
DALYs for 2010 totaled 33,407,000 for a population of approximately 55.5 million people, with
HIV/AIDS attributable for 40%.25,26 Our estimate should be considered relative to the population
at risk for RVF. As of 2011, 1,096,854 households were involved in livestock production activities,
out of 14,450,161 households total.27 We present DALYs here as a common metric for health
burden; while we do not translate it directly to monetary impact, it is a basis for healthcare service
utilization and productivity loss estimates (below).
b) Healthcare and associated costs
RVF is coded for billing purposes as ICD-10 code ZA 11 for ‘other infectious diseases’ (previously
ZA 10); however, we could not obtain RVF-specific healthcare service usage and pricing data.
There is no treatment for RVF other than supportive therapy. From a study of South African cases
occurring in 2008, half (n=4) of the laboratory-confirmed cases documented in the sample required
hospitalization. Hematological and biochemical testing was conducted by a private laboratory
company, with eight clinical pathology test values reported (e.g. platelet count, C-reactive
protein).28 We estimated that for the 302 confirmed cases, all visited a healthcare provider
(requisite for specimen collection), with the majority (n=212) via outpatient visits, 25% (n=75)
requiring short-term hospitalization for an average of four days each and 5% (n=15) undergoing
hospitalization for an extended stay of 10 days related to meningitis or viral hemorrhagic fever.
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We estimated that 12 cases would experience chronic disease and seek additional services in the
form of at least one specialist visit. Healthcare utilization was specific to the 2008-2011 outbreak;
in the 2018 outbreak none of the six farm workers experiencing symptoms consistent with RVF
reported needing hospitalization.22
We estimated medical care costs for cases using the WHO-CHOICE 2010 data for inpatient
and outpatient health service delivery in South Africa for 2010 (Table 2.3; see source values in
Table A2.4). CHOICE data are disaggregated by primary, secondary and tertiary hospital levels,
which roughly correspond to South Africa’s district, regional, tertiary/national central/specialist
categories of public hospitals. We assumed costs were inclusive of pathology testing and that RVFspecific diagnostics were covered by the national laboratory (see below). For non-medical costs
associated with treatment, we estimated average transport to and from hospital or other medical
visits at R90, and pharmacy costs at R200 per patient visit.
Based on estimated average costs and utilization, healthcare and associated spending for
RVF symptom management totaled at least $39,579. This estimate is likely conservative as it
does not account for possible additional patients presenting on suspicion of RVF, or more
intensive services associated with patient care. Severe cases of RVF elsewhere have required
dialysis to manage organ failure symptoms; in South Africa, dialysis services for one patient
alone can cost in the thousands to tens-of-thousands of Rand. Additionally, while guidance
released from the NICD (see below) encouraged the WHO’s standard precautions for infection
prevention and control in healthcare settings, there may have been additional facility costs
incurred from concern over nosocomial (healthcare-acquired) infection risk. There is also likely
an underlying cost-of-services difference in public versus private healthcare costs; for the sake of
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payer analysis, we estimated that half the patients presented at private facilities (out-of-pocket or
insured costs) and half at public facilities (freely provided by the government).
c) Productivity losses:
Reduced health status is an impediment to workforce productivity. There are various methods for
calculating productivity loss due to disease and early mortality. We used DALY estimates (Table
2.2) as a basis for calculating for workforce or school absenteeism (hereon “absenteeism”) and
other productive life losses. To avoid possible double-counting, we focused productivity losses
solely on cases and caregivers; for productivity losses from farm and abattoir closures and other
disruptions in wage generation, we assumed these impacts would be encompassed by farm and
industry impact estimates (below).
The majority of cases (Table 2.1) were farmer or abattoir workers or other livestock-related
professions. On average, agricultural workers tend to be low-earning, with a reported 70% making
<R2,500 per month as 2016.29 However, given likely wage outliers (e.g. veterinarians), we used
Gross National Income (GNI) per capita as an approximator for mean productivity loss. GNI is
similar to an average Value of Statistical Life Year for South Africa (see Appendix). As most cases
and all fatalities in the 2008-2011 outbreak occurred in 2010, and as disease severity data was not
otherwise disaggregated by year, we grouped productivity loss in that year. All values were
calculated as attributed to the year they occurred as a cost attributable to that year; however, other
studies may extend these costs into forward years to estimate ongoing productivity loss.
Using data from Tempia et al. (which found that mean absenteeism by caregivers ranged from
.5 days for medically-attended influenza-like illness to 1.4 days for Severe Acute Respiratory
infections),30 we estimated all confirmed cases were associated with an average of one day of
caregiver absenteeism (to account for variations in case severity and duration of illness) using GNI
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per capita as above (Table 2.4). We did not calculate caregiver losses for the 2018 cases. In total,
an estimated $5,084,145 was lost in case and caregiver productivity from RVF.
d) Public health services
Public health activities related to RVF were mainly mobilized in response to outbreaks, including
epidemiological investigation, risk communication, laboratory testing, and guidance development
(e.g. the Health Workers’ Guidelines on Rift Valley Fever released by the NICD) via national and
provincial efforts.
National: RVF can be suspected on the basis of clinical and exposure history, but laboratory
support is required to confirm diagnosis. In the 2008-2011 outbreak, government-provided testing
was conducted on suspected human cases through the Arbovirus Reference Laboratory of the
National Institute for Communicable Diseases (NICD). The NICD and Department of Health
provided healthcare professionals with RVF case definition, clinical and differential diagnosis and
specimen collection guide for testing. The NICD is part of the National Health Laboratory Service
(NHLS) network. Samples were transported to the nearest local NHLS laboratories and reached
the reference laboratory in compliance with guidelines through the existing NHLS infrastructure
and transport network connectivity. Testing involved a combination of real-time reverse
transcription (RT) PCR, loop-mediated isothermal amplification assays, virus isolation,
hemagglutination-inhibition assays (HAI), or IgM ELISA. To approximate cost, we calculated
cost of three tests (PCR (R800/sample), HAI (R124), and ELISA (R140), i.e. R1,064/specimen)
for all 2,621 total human specimens tested that led to the 302 laboratory-confirmed cases
specimens (see Table A2.5), or R2,789,808. In the 2018 livestock outbreak, human cases were
discovered in the course of epidemiological investigation. Blood samples were collected from ten
people of which eight reporting illness and testing was conducted at NICD using four tests: (9 real-
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time RT-PCR, 55 HAI, 24 RVF inhibition ELISA IgG, and 16 RVF IgM ELISA); we estimated
these totaled R20,000. The eight positive also went for eye examinations (personal
communication, NICD).
While RVF research activities are undertaken in the country, publicly-financed RVF surveillance
activities in inter-epidemic years are limited and not considered systematic. Outside of extramural
research programs, we estimated investment in these activities at R80,000 annually from 2012
onward, accounting for screening of all suspected arbovirus cases using HAI plus testing of some
cases by ELISA IgG (personal communication, NICD). Collectively, national public health
activities for RVF between 2003-2018 were estimated at $334,600.
Provincial public health response:
To estimate the cost of provincial public health response for epidemiological investigation and
outreach (i.e. fuel and materials) to high-risk populations (i.e. farm and abattoir workers,
veterinarians, human healthcare providers), we used a per-case estimate of R1,000, i.e., R302,000
(Table 2.5) to approximate the total cost incurred by provincial health departments across the
country ($31,302).

AGRICULTURE
As officially reported by the South African government to the World Organisation for Animal
Health (OIE), between 2003-2018 South Africa had 700 unique RVF outbreaks (occurring in
2008-2011 and 2018), with 17,946 animal cases recorded, of which 11,942 animals died or were
killed and disposed of. Several factors make approximation of livestock losses specific to RVF
challenging, particularly its multi-year occurrence over different provinces and in different species,
uneven restrictions on international trade, length of trade bans, and the overall economic context.
A prior study set a foundation by estimating farm-level losses (see below). Beyond farms, RVF
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was reported to have ripple effects along the value chain not encompassed in their estimate,
including forced closures of abattoirs (slaughter houses), buyers and brokers, services (e.g.
shearers and processors), and exports (among others). Overall, the percentage value-added (i.e.,
net output) to GDP from agriculture, forestry, and fishing consistently declined between 2008–
2012 (2.86-2.17%, respectively); however, it is unclear if a portion of value decline was reflective
of RVF losses or exogenous factors (e.g. the global recession, greater relative GDP value from
tourism or telecommunications for the 2010 World Cup, etc.) For livestock impacts, we estimated
costs of a) Farm level; b) meat and wool industry; c) vaccination; d) other control measures; e)
veterinary services.

a) Farms. Based on primary data collection from 150 farms in three highly-affected provinces
(Eastern Cape, Northern Cape, and the Free State), Mdlulwa and Klein (2015) found that official
animal losses were likely far under-reported. Upscaling their findings to national level, they
estimated financial losses at the national level from mortalities, abortions and reductions in milk
output in 2008-2010 were R295.26 million. Sheep losses (the major affected species) were the
major driver, with a reduction of 400,000 sheep across the three provinces between 2008-2010.
Their estimate was not inclusive of the cost of vaccines, insect repellant dips and terramycin (see
below), reductions in the value of hides and wool, worker productivity or health, and international
trade restrictions (which we estimate below). Most farms reported that diagnostics were conducted
by the government with no costs incurred to farmers. For the isolated 2018 outbreak, 335
fatalities/abortions were reported from a flock of 600 sheep on a single farm (OIE report). The
outbreak was detected in response to investigation from a private veterinarian and testing at a
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private laboratory. We estimated the affected farm incurred losses from animal mortalities at
R1,000 per animal, or R335,000 in total ($32,173,806).
b) Industry
We examined two leading livestock commodities, wool and red meat, assuming the maximum
economic yield of livestock would be reflected in its final sale or export value (i.e., the price of its
final sale in South Africa would exceed all value chain goods and services), to roughly estimate
impacts.
Wool. As of 2009, the wool industry was valued at ~US$900 million (Farmers’ Weekly). On
August 18, 2010 a trade ban went into effect that halted movement of wool and mohair products
out of the country.31 Movement of wool and hides are not restricted under OIE guidelines, but
China’s refusal to receive woolen goods unless farms of origin could be certified as RVF-free
required a postponement of auction and exports free (China was the majority buyer for South
African wool). Qualitatively, losses to the wool sheep industry were described as “enormous”,
with the National Wool Growers’ Association stating losses to the sector of R2.2 billion from
2010-2012.32 Wool is aggregated by buyer associations in South Africa; impacts are typically
deferred given timing of shearing, collection, and bulk sale at auction. Production declines were
observed during 2009-2011, particularly in the Free State and Northern Cape provinces (Figure
A2.1). Production reflects material processed in South Africa but may be sourced from
neighboring countries. Compared to the 2009/2010 season and 2011/2012, total wool production
in South Africa dropped by 3.5 million kilogram (kg) (48.3 million to 44.8 million kg, respectively)
(Figure 2.3). Greasy (unprocessed) wool constitutes 75% of woolen exports. Consistent with the
ban, gross export value for greasy wool from South Africa to China dropped by nearly half from
2009 to 2010. Gross export values from South to the world did not appear to suffer, and steadily
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rose from 2010 onwards (see Figure A2.1); export value of wool to China also appeared to rebound
from 2011 onwards. There are several explanations: the weaker rand stimulated export value once
the ban was lifted in October 2010;33 high pricing of wool based on global demand, including from
European importers, made the industry more lucrative and helped restore South Africa as a leading
supplier;33 and gross export value increase likely reflected increased total trade volume to
compensate for held quantities of wool after the ban was lifted (alternately, export trends may be
an artifact of timing of reporting and poorly correlated to timing of the market response). Industry
measures, including process to certify wool farms as disease-free, likely helped restore confidence
and regain market share. The stated losses by the wool industry likely represent short-term effects
of the ban, particularly cash flow and market access for domestic value chain inputs and long-term
animal stock losses.
Red Meat. Unlike wool and hides, the OIE regulations have internationally-accepted trade
consequences for meat and milk products. Impacts to red meat production (e.g., sheep, cattle, goat
meat) were reported as detrimental but it is unknown how long the ban was in effect (although we
can assume it extended beyond the period for wool). A projection from the Red Meat Producers
Organisation noted that the cost of major export bans from RVF could total nearly R2 million. 34
However, in 2010 South Africa reported increased sale of meat on the domestic market, which
may have compensated for reduction in meat export volumes. Red meat did not appear to
experience notable loss of consumer confidence or substitution effects.
Overall. The country-wide scale of the 2008-2011 outbreaks had a visible market response. Based
on the 2.2 billion impact stated by the wool industry, plus up to 2 billion potentially forfeited from
a red meat ban, we used a conservative estimate to avoid double counting with farm impacts. We
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assumed 15% of possible impacts (i.e., R630 million) would be valid as a minimum estimate,
extending it over three years ($61,995,658).
Countries are required to undergo additional screening for multiple years to restore ‘freedom
from disease’ status. It is unclear to what extent these measures imposed additional costs beyond
the outbreak period. For the 2018 outbreak, its isolated geographic nature seemed to limit major
effects on markets, although it was reported to have localized trade effects, with neighboring
countries blocking imports within 72 hours of the outbreak announcement.32 Following major
losses, the wool and red meat industries have taken measures to reduce potential impact of RVF
to their industries, including via funded studies, risk communication and alerts to members (used
in 2018 and 2019, both high rainfall years, to encourage preventive vaccination), and convening
of an Animal Health Forum. We used an estimation of R1 million per year for 2013-onward for
these activities ($463,734).
Vaccination: Livestock vaccination is the recommended prevention strategy for RVF in animals
and humans. Three vaccine types (Live, Clone 13, and Inactivated) are licensed for use in South
Africa. The vaccine is sold in 100-dose vials for administration to 50 (Inactivated) to 100 (Live
and Clone 13) animals per vial. Vaccine sales information was provided by the producer. Between
2003 – 2018, a total of 524,115 vials were sold. Sales ranged from a low of 3,024 vials in 2004 to
a high of 199,648 vials in 2010 (see figure 2.3). A range of pricing has been reported, from ~50
cents per dose for government to R2.3-5.01 for farmers over the outbreak period, depending on
species.34,35 At a minimum cost of 41 cents per dose, or R41 per vial, this represents a total cost of
R21,488,715 ($2,166,635).
As the disease is not state-controlled, government provision of the vaccine via public
veterinary services is typically limited to smallholder or communal farms and only during
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outbreaks.36 Mdlulwa and Klein found that of those that vaccinating against RVF during the 20082010 outbreak period in three provinces, 33% reported receiving it for free. In 2010, for example,
it was reported that the Western Cape Department of Veterinary Services had distributed 80,000
units of the vaccine at no cost to farmers, and during 2015-2018 contracts were established to
supply vaccine to provincial veterinary services.37 For payer assessment, we estimated 33% of
RVF vaccine sales were publicly-financed, with farmers paying the remainder.
d) Other control measures
Prior findings reported that 9% of farmers used dip (insecticide) and 6% used terramycin (an
antibiotic) as control measures against RVF during the outbreak. They estimate the cost of these
measures, plus vaccination, totaled R41,865,369 (2014 Rand) for the Eastern Cape, Northern
Cape, and the Free State. Vaccination represented only one-fifth of this amount;9 therefore, it was
reasonable to assume that their estimate could approximate spending on dip and antibiotic alone
for control measures across all provinces ($4,332,223) and would not overlap with our separate
estimate of vaccine costs above.
e) Veterinary Services
Through the Department of Agriculture, Forestry and Fisheries, national and provincial
Veterinary Services provide outbreak investigation and response, as well as ongoing livestock
health support.
National: Diagnostic tests for suspected cases in animals during the 2008-2011 outbreak were
conducted at the ARC–OVR Biotechnology Laboratory. We estimated that laboratory-confirmed
animal cases (14,342) represent approximately 75% of all animals screened, i.e. 19,000. We used
the same testing costs as for human samples (i.e., R1,064/animal). As we did not know screening
counts per year, we calculated the total animal diagnostics amount during the course of the
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outbreak instead of yearly, with an estimated cost of R21,428,865.08. A previous study reported
that no costs were incurred by farmers for diagnostics during the 2008-2011 outbreak;9 thus this
cost was incurred solely by the government.
Provincial: Based on Veterinary Services budget information from a highly-affected province for
the 2008-2011 outbreak period, we divided incidence of animal cases/province38 to estimate costs
for all provincial veterinary services. Reported cost items included sampling supplies,
communications, cold storage, tents and containers, power for roadblock, personal protective
clothing, and firefighter services for vehicle disinfectant. As travel costs were not available but
likely a significant aspect of provincial response given distances within provinces (e.g. between
farms), travel expenses (fuel, vehicle, overnight stay, field per diems) were estimated at an extra
20% of provincial costs. Together, provincial veterinary service costs were estimated at
R1,443,438.10. Excluding vaccine costs captured elsewhere, total national and province veterinary
services costs were estimated at $2,337,350.

Environment and Natural Resources
We assessed environmental impacts in the form of a) conservation losses; b) wildlife ranching
(wildlife activities and products); and c) pollution.
a) Conservation losses:
South Africa is one of the highest-biodiversity countries in the world.39 Disease in wild ungulates,
particularly springbok, bontebok, and buffalo, was observed in 2011 (Pienaar and Thompson
2013). While evidence of RVFV circulation and sero-conversion has been detected in buffalo, to
date notable productivity impacts have not been reported in South Africa (Beechler et al. 2013).
We considered the effects of RVF on springbok (Antidorcas marsupialis) specifically. Theoretical
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impacts could include ecological impacts from species reduction (e.g. changes in grassland soil
disruption, food chain, seed dispersion), activation of wildlife management services (e.g.
veterinary care, monitoring), wildlife product yield, and cultural services (as the national animal
of South Africa). The population is designated as ‘Least Concern’ on the IUCN Red List of
Threatened Species, based on its abundance and overall increasing population status.40 Therefore,
we assumed no significant enhanced population management measures were enacted related to
RVF, especially given South African National Park’s (SANParks) minimal-intervention strategy.41
b) Wildlife ranching:
As of 2018, wildlife ranches accounted for 15.3% of South Africa’s land surface area. The sector
is comprised of three main revenue streams: 1) wildlife ranching, 2) wildlife activities (viewing
and hunting), and 3) wildlife products (meat, hide, and decoration). The sector is prioritized for
growth by the Department of Environmental Affairs, viewed as integral to the country’s
conservation strategy.39 We estimate that RVF had impacts of at least $2,969,831 based on:
Hunting: Springbok, impala, blesbok and kudu were the four most-hunted wildlife species based
on reports from 2006 and 2013 (subsequently, this had shifted to impala, warthog and buffalo in
2015/2016) (PHASA).42 In 2006, springbok comprised 29% of hunted animals. Trophy hunting,
via both professional and recreational (“cultural”) hunters, generated R2.3 billion in 2006.
Charismatic megafauna (i.e. the “Big 5”: buffalo, elephant, leopard, lion, and rhinoceros) are major
earners for trophies. As of 2013, 62% of wildlife hunters reported using South African taxidermy
versus shipping pre-taxidermy; the value of this industry was estimate at R200 million in 2006.42
We estimated a 5% decline in taxidermy demand in 2011 (R10,000,000) due to RVF based on the
combination of wildlife mortalities and the international trade ban. The OIE Code does not
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differentiate between domestic and wild species, making all ruminants potentially subject to trade
bans at the discretion of export and import country regulations.
Game meat: The limited national records available on the scale of private game farming was noted
in 2011, with plans for improved tracking through national authorities. As of 2011, game meat
consumption domestically was estimated at 1,350 tons, plus an export value of approximately R15
million in 2011.42 The total game capture industry’s reported revenue generation is over R100
million per year. Significant springbok mortality and trade bans associated with loss of revenue in
2011 were reported by the game harvest industry (personal communication, 2019). Using industry
numbers, we estimated that 1,200 tons of springbok meat was harvested and sold in 2010, at a
price of R37/kg. In 2011, we estimated that half that amount was harvested, translating to a 544,311
kg reduction, or R20,139,507 in lost revenue.
c) Pollution:
Insecticide use presents risks for environmental degradation risk (to water sources or non-target
species, including humans) via toxicant exposure, and may contribute to insecticide resistance. As
of the 2010 outbreak, outdoor insecticide spraying by the government was not permitted due to
environmental impact.35 At farm level, insecticide “dipping” of livestock is commonly used for
control of vector-borne diseases in South Africa; we could not determine what portion of damages
were exceeded from RVF beyond routine use. Relative to crop use, environmental damage from
livestock-associated disease prevention was reported as limited (personal communication,
SANParks); thus we did not include pollution impacts in our analysis.

TOURISM

Park revenue. Overall, tourism rose in South Africa during the outbreak, from ~7 million tourists
in 2009 to 8.3 million in 2011.43,44 The 2010 FIFA World Cup was a major driver of this increase;
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however, the number of visitors rose further in 2011.43 A media statement from the South African
government noted that RVF was not a risk to World Cup attendees given that transmission was
associated with exposure to infected livestock; the statement also noted there was no risk to visitors
to game parks.45 Parks and other natural areas, however, saw an 8.5% decline from 2009 to 2010;
expense, perceived access challenges, and the global economic downturn are cited as possible
contributors.43,46 South African National Parks (SANParks) manages a network of 19 parks
representing of 67% of state-managed protected areas. In addition to conservation objectives, the
park system provides ecotourism revenue through lodge concession fees, restaurants, and
souvenirs. As of 2017, domestic visitors accounted for 70% of SANParks visitors. Lodging
concessions at national parks are managed via public-private partnerships and typically attract a
higher portion of international guests compared to alternatives such as camping. Between 20072017, 2011 was the lowest-occupancy year in lodging concessions. In 2009, average concession
occupancy was 50.7%, declining to 46.2% in 2010 and 40.7% in 2011;46 however, while falling
between March 2009-2010 (R38.6 million to R35.6 million per year), total lodge concession
earnings rebounded as of March 2011 (R42.0 million) (Table 2.6), with a large increase at Kruger
National Park’s Singita Lebombo lodge.41 Therefore, given inconsistencies, we did not conclude
there were likely noteworthy tourism impacts attributable to RVF ($0).

FINANCE
Tax revenue. Avoided value-added tax (VAT) is assessed on particular livestock products and units
(e.g. per carcass or liter of milk); given the variety of products sold, we used a rough approximation
of 14% VAT for industry-level losses, applying it to losses of approximately 660.14 million (Table
7). We did not apply taxation value to farm losses, assuming taxation would occur at point of sale
in the value chain captured by the wool and red meat sector values.
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We estimate that at least $9,095,169 in tax value was forfeited over 2010-2012. These are rough
approximations and likely conservative; nevertheless, they suggest substantial losses of tax capture
as a consequence of the RVF outbreaks.

CUMULATIVE IMPACTS
The majority of costs occurred during the major epidemic period (Table 2.8). For cost items
assessed, estimated total impacts between 2003-2018 ranged from $120,600,299 (base scenario)
and $224,418,696 (multivariable sensitivity analysis) (see below). Variations in wool and sheep
industry losses had the greatest magnitude of effect on cost. For the base scenario, costs were
distributed by sector as livestock (85.4%), Finance (7.5%), Health and Productivity (4.6%), and
Environment/Natural Resources (2.5%) (Figure 2.4). Even when using our upper estimate for
average vaccination cost (see sensitivity analysis below), the ratio of prevention to response costs
over the fifteen-year period was $1.64 : $10.42 (see Table 2.9 for prevention items).

Sensitivity analyses
Our base estimates are conservative. We conducted one-way and multivariable sensitivity
analyses, varying major cost items with high uncertainty and magnitude of impact (Table 2.10).
For vaccine cost, the price differences can also be viewed as a rough indicator of payer
differences, i.e. costs if purchased fully by either the public or private sector. Our calculations
show wide potential differences in impact based on livestock industry parameters. Our analysis
intended to estimate magnitude of losses and identify the range of impacted stakeholders.
However, all rely on assumptions and should be viewed as a basis for further work by each
sector to quantify relevant losses more precisely.
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Discussion
Our base societal estimate of $120,600,299 is 3.3 times higher than the prior estimate of farmlevel livestock impacts for South Africa.34 Our findings indicate impact is concentrated in major
outbreak years, indicating low investment in prevention measures in inter-epidemic periods.
Livestock sector losses, in the form of wool and red meat value chains and farm-level animal
mortality and production losses, represented the majority of costs. For the sake of clarity, we
presented cost items by typical sectoral mandates in the South African context; however, these are
superficial breakdowns and alternate groupings may be valid. Future collaboration (i.e., One
Health) on surveillance and response could potentially optimize resources across sectors.
Previous methodologies have suggested starting with a consideration of the direction of impact
(positive or negative) and magnitude (e.g., ++, -) for rapid assessment where there is cursory
information and to identify relevant stakeholders.47 That may be sufficient for engaging in dialogue
with multiple sectors, but does not provide a quantitative basis for cost-benefit analysis. This
analysis conducted detail assessment of specific cost items, with varying levels of confidence. In
terms of highest confidence, WHO-reported CHOICE information for health care cost was
available for 2010, the year most illnesses and deaths from RVF occurred. While cost of care may
be above or lower than average depending on location in the country, CHOICE uses an average
values for a given country, which was appropriate given the range in human cases across the
country; additionally, although we had to make some assumptions in selecting type of healthcare
center from the CHOICE categories (e.g. primary vs. tertiary, inpatient versus outpatient),
alternative selections would not have changed healthcare service utilization cost estimates
substantially. The lowest confidence cost item is the impact to the livestock sector, as we made
conservative assumptions to avoid double-counting across different data sources and estimated
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some cost items as a percentage of projected industry losses. It is unclear what portion of projected
losses represent true losses, and to what extent expected gains may have been time-deferred when
trade bans were lifted. South Africa has many industries – e.g. tourism, telecommunications,
manufacturing – that contribute to GDP, making national effects of even a major RVF epidemic
challenging to parse out. In comparison, effects may be less easily lost in overall trade and
economic flows in countries where livestock is substantial portion of GDP.
The sensitivity analysis attempted to account for confidence issues of cost items, but for most
effective decision-making, it will be beneficial to engage stakeholders to improve understanding
of the scope and magnitudes that they have documented or perceived for their sector, as well as
the value they ascribe to prevention. Future studies may conduct cost-effectiveness analyses to
determine if proposed prevention and control strategies meet given threshold(s), with confidence
intervals examined in sensitivity analyses, providing a pragmatic approach to dealing with
uncertainty in return on investment and varying levels of acceptable thresholds across different
stakeholders and payers.
The livestock sector faces many threats that warrant budget attention, including other diseases
(e.g. anthrax, brucellosis, FMD), drought, theft, and predation; it is naïve to suggest there should
be consistent prioritization of RVF. However, our findings suggest there is some level of
suboptimal use of existing resources related to RVF. While regular (annually or at least in years
with above-average rainfall predictions) vaccination of livestock is the recommended prevention
strategy, our findings indicate low investment in vaccination during inter-epidemic periods, with
the majority of vaccine sales seen during outbreaks. Emergency vaccination against RVF is
typically thought to be sub-optimal for several reasons: increased likelihood of spread in herds
during active transmission periods resulting from reuse of needles for multiple animals; timing of
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vaccination may occur too late to be efficacious (i.e., after animals are infected but before
displaying clinical signs); and vaccination requires a 10-day hold period before milking can
resume, which adds to production losses. In addition, inconsistent cold storage is a persistent
concern for vaccine efficacy. Inconsistent supply and demand of RVF vaccines, and time required
for upscaled production and distribution, also make emergency use a poor sole strategy to rely on
for control of RVF.
Losses on farms that initiated vaccinated once the outbreak started in 2010 were more than
double that of farms that vaccinated before the outbreaks occurred.34 We estimate that >20% of
RVF vaccine use may be ineffective based on the above vaccine administration issues. The
reported use of terramycin by farmers in the 2008-2010 outbreak also represents wasted resources,
potentially contributing negative externalities via antimicrobial resistance. Redirecting ineffective
resource use to prevention should be a minimum target. Lost tax revenue from forfeited livestock
sales demonstrates far-ranging costs and the importance of accounting for multisectoral impacts.
Possible cost recovery strategies to fund improved prevention efforts should be considered; for
example; VAT revenue from dairy products and slaughtered animals was proposed in
parliamentary committee discussions as a potential financing option.35
Coordination. Beyond weekly meetings during the outbreak and a joint risk communication
statement, we did not find evidence of strong coordinated resource mobilization and activities at
national level. A parliamentary report noted that “resources to deal with the problem had not been
budgeted for, and a joint approach needed to be made to Treasury for additional funding”.35 Some
efficiencies in resource use were identified. At provincial level, a Veterinary Services department
allocated funding to fire services, leveraging their existing equipment for vehicle disinfection. The
investment from wool and red meat industry groups is also encouraging given their credibility and

62

effective information dissemination channels. There is also likely high utility in the sustained role
of industry in the Animal Health Forum, organizing a rapid response for the Foot and Mouth
Disease outbreak in 2019 in collaboration with the government to demonstrate safety of exports to
overturn the resulting trade ban. Nevertheless, as not all farmers have access to these industry
channels, it is critical that this infrastructure be viewed as a reinforcement rather than a replacement
for an enhanced government stance against RVF.
Limitations. While we sought to verify information with official reports, poor information
availability and potential for recall bias over the 15-year time period are obvious limitations of our
study. There may be other relevant impacts we did not account for, including potential
consequences of staff time and other fixed resources diverted to RVF, which may be substantial
in large epidemics.48 The varying methodological procedures of cost estimation for each sector,
and even within disciplines, required methods selection based on appropriateness for the South
African context. We believed it was critical to attempt a good-faith estimate of all relevant impacts
to ensure they were made visible; however, we recognize that some stakeholders may find it
ethically problematic to assign monetary values to certain impacts or may view value in other
terms (e.g. an inherent value of wildlife). On this basis, we sought to be inclusive in our
information gathering and reflect uncertainty in our sensitivity analyses. Incompatibility of
different data sources and metrics made broad approximations necessary; however, it is unlikely
that more precise data would shift the overall magnitude of impacts. Our initial estimates can serve
as a basis for future work to make zoonotic disease impacts more tangible and incentivize diverse
stakeholders to work together for threat reduction. The sectoral distribution of impacts provides a
basis for cost-benefit analyses to avert costs across society – which can be significant when looked
at cumulatively – and inform viable cost-sharing options (see Roth et al. for an example).49
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Strengths. This paper demonstrates a practical approach to account for monetary and nonmonetary impacts of disease and translate them into an overall societal impact estimate. The data
sources can be adapted to use for other diseases and settings, taking into consideration different
contexts of affected populations and sectors to guide reasonable parameters for base and sensitivity
values.

Conclusion and Recommendations
Analysis of multi-sectoral impacts of RVF can inform prevention and control decisions under
South Africa’s National One Health Forum and national action plan for health security, including
for risk monitoring and vaccine production, distribution, and pricing. Economic impact analysis
may also enhance after-action reviews of outbreaks to identify where coordination can be
beneficial. Future research can improve precision through micro-costing studies at household level
and along the value chain.
The costs incurred from outbreaks– and the low level of investment in prevention between
them –can also inform sectoral policies. Even if largely reliant on farm-level decisions for vaccine
uptake, public sector investments can promote effective risk communication and encourage a
whole-of-society approach towards risk reduction. Overall, our study reinforces needs and
opportunities for more consistent and effective vaccination practices, enhanced coordination of
resources in peacetime and outbreaks, and highlights a significant societal value that may be
derived from protection against RVF. We encourage stakeholders in South Africa and elsewhere
to expand on our initial analysis to routinely track multi-sectoral impacts of zoonotic diseases as a
basis for developing cost-effective resource allocation strategies.
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Figure 2.1 Impact inventory for hypothesized cost items associated with RVF in South Africa, by sector.
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Table 2.1 Characteristics of human laboratory-confirmed RVF cases and deaths, 2008-2011. Adapted
from Archer et al. 2013. Years Life Lost our calculations based on WHO Life Tables for 2010.
Characteristic
Male sex*
Age group, y†
0–9
10–19
20–29
30–39
40–49
50–59
60–69
≥70
Occupation‡
Farmer or farm worker
Animal health worker
Abattoir worker, butcher, or hunter
Farm resident (nonworker)
Non–animal related occupation
Other/unspecified
*Known for 302 case-patients.
†Known for 300 case-patients.
‡Known for 289 case-patients

Cases
No. (%); N = 302
262 (87)

Deaths
No. (%); N=25
N/A

Deaths
Ave. Years Life Lost (%)

1 (<1)
16 (5)
67 (22)
47 (16)
68 (23)
53 (18)
30 (10)
18 (6)

0 (0)
1 (4)
5 (20)
3 (12)
6 (24)
7 (28)
2 (8)
1 (4)

0 (0)
47.20 (7.51)
190.25 (30.26)
90.00 (14.32)
143.10 (22.76)
125.65 (19.99)
24.6 (3.91)
7.85 (1.25)

173 (60)
37 (13)
32 (11)
5 (2)
42 (15)

12 (48)
2 (8)

11 (44)

Table 2.2 Disability weights for selected conditions and estimated years life with disability and years life
lost attributed to recent RVF outbreaks in South Africa. Source: Salomon et al. 2015 and our
calculations.
Disability Weight

Incidence

Duration

YLD

Acute episode, mild
Acute episode, mild

0·006
0·006

2,777
212

3 days
1 week

.137
.024

Acute episode, moderate
Acute episode, severe

0·051
0·133

75
15

2 weeks
1 month

.368
.153

0.184

6

Permanent
(14.67 years)

16.196

.402

6

35.384

1

25

Permanent
(14.67 years)
7.85-47.2 years
(see Table 1)

0.006

6

1 week

.001

Disability

YLL

2010-2011 outbreak
Infectious disease

Distance vision

Severe vision impairment
Motor impairment

Severe
Death

628.650

2018 outbreak
Infectious disease

Acute episode, mild
TOTAL DALYs, ALL YEARS

680.913
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Table 2.3 Direct and indirect costs associated with medical care for RVF patients.
Cost Item

Level*

N

Cost
(Rand)

Duration

Total (Rand)

Medical costs
Outpatient visit
Inpatient admission, short-term (per day)

P
S

212
75

R92.4
R601.51

Once per illness
4 days

R 19,588.80
R180,453.00

Inpatient admission, extended (per day)

S

15

R601.51

10 days

R 90,226.50

Specialist out-patient (infectious disease,
ophthalmology, neurology)
Associated Costs
Transport
Pharmacy
Total

T

12

96.3

Once for chronic
condition management

R1,155.60

314
314

90
200

Per visit (Roundtrip)

R28,260
R62,800
R382,483.90

*P=Primary hospital; S=Secondary hospital; T=Tertiary hospital
Sources: WHO-CHOICE (2010) and our estimates.
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Table 2.4 Estimated production losses using per-capita Gross National Income (GNI), South Africa.
Source: GNI estimates from World Bank; calculations based on YLD and YLD (DALYs) Table 2.2
Base Calculation using GNI per capita, Atlas method (current US$)
GNI2003-2007

GNI2008

GNI2009

GNI2010

GNI2011

GNI2012-2017

GNI2018

$2,920 $5,910

$5,980

$5,850

$6,190

$6,990

$7,570- $5,410

$5,750

Cases
Mild episode – 1
day out (2010:
2,777)
Mild episode - 1
week out (2010:
224 cases; 2018:
6 cases)
Moderate
episode- 2
weeks out (75
cases)
Severe episode1 month out (12
cases)
Permanent
disability- 14.67
years (12 cases)
Death- Ave.
YLL of 25.125
(25 cases)

$47,094.88

$0.00

$0.00

$0.00

$25,236.15

$0.00

$0.00

$663.46

$0.00

$0.00

$0.00

$17,855.77

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$7,142.31

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$1,089,687.60

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$3,891,343.50

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$5,078,360.21

$0.00

$0.00

$663.46

Total, all cases
Caregivers
Ave. 1 day/case

$0.00

$0.00

$0.00

$5,121.59

$0.00

$0.00

$0.00

Total, cases and
caregivers, by
outbreak period

$0.00

$0.00

$0.00

$5,083,481.80

$0.00

$0.00

$663.46

Total, all years

$5,084,145.26
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Table 2.5 Laboratory-confirmed human cases by year and province, 2008-2011 and 2018 outbreaks.
Source: Archer et al. 2013 and van Vuren et al. 2018.
Year

Cases (%)

Provinces with Human Cases

2008
2009
2010

17 (5.63)
7 (2.32)
241 (79.80)

Gauteng, Mpumalanga, Limpopo
KwaZulu-Natal, Northern Cape
Free State, Northern Cape, Eastern Cape, Western Cape, North West

2011

37 (12.25)

Eastern Cape, Western Cape, Free State, Northern Cape

302 (100%)

All

6 (100%)

Free State

Total, 20082011
2018

Figure 2.2 Wool production by season. Circle indicates periods of impact from RVF. Total=all wool
produced in South Africa, regardless of country source; SA provinces= wool sourced from South Africa
specifically. Courtesy of the National Woolgrowers Association.
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Figure 2.3 RVF vaccine sales, by number of doses, 2001-2019 (through October 2019). Data courtesy of
Onderstepoort Biological Products.

Rift Valley Fever Vaccine Sales, 2001-2019

Doses (number of animals)

20,000,000

18,000,000
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Inactivated
Total

12,000,000

10,000,000

8,000,000

6,000,000

4,000,000

2,000,000

0
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019

Year

Table 2.6 National Park Lodge Concessions. Source: SANParks.

Year

2009

Lodge
Concession
Revenue
R38,629,843

2010

R35,665,000

2011

R42,037,000

2012

R40,878,000
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Table 2.7 Items assessed for tax value loss from RVF outbreak.
Item
Wool and red meat sector
Springbok
Taxidermy
Total

Cost
R630 million (2010-2012)
R20,139,507 (2011)
R10 million (2011)
R660,139,507.00

Tax value loss
14%
R92,419,530.98

Table 2.8 Main costs grouped by sector, 2003-2018. Minimum estimate.
Main sector or cost item
Health & Productivity
Livestock
Environment
Tourism
Finance (taxation)
Total

Estimated cost
$5,489,626
$103,045,672
$2,969,831
N/A
$9,095,169
$120,600,299

Main Year(s) Incurred
2010
2008-2012
2011
N/A
2010-2012

Figure 2.4 Proportion of cost by sector.

Total Portion by Sector, 2003-2018
Human Health
and Productivity
Livestock
Environment
Tourism
Finance
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Table 2.9 Prevention Costs.
Main Prevention Investments
Vaccination*

$15,853,265

Industry risk reduction

$463,734

Arbovirus surveillance

$44,555

Risk alert

$3,390

Total
$16,364,943
*high vaccine pricing parameter, see sensitivity analysis (R300
per vial).

Table 2.10 Sensitivity analyses for cost variables, with comparison to base values.

Cost Categories
Healthcare and
associated costs
Productivity
losses
Public health
costs

Base

Sensitivity Parameters (varied parameters in yellow)
GNI: 6x
30% potential
R300/vial
(deaths)
industry losses
vaccine
Multivariate

$39,579

$39,579

$39,579

$39,579

$39,579

$5,084,145

$24,540,863

$5,084,145

$24,540,863

$24,540,863

$365,902

$365,902

$365,902

$365,902

$365,902

Farm losses

$32,173,806

$32,173,806

$32,173,806

$32,173,806

$32,173,806

Industry losses
Other control
measures

$61,995,658

$61,995,658

$123,991,316

$61,995,658

$123,991,316

$4,332,223

$4,332,223

$4,332,223

$4,332,223

$4,332,223

Vaccination
Veterinary
services
Environment/
wildlife losses

$2,166,634

$2,166,634

$2,166,634

$15,853,265

$15,853,264.50

$2,377,350

$2,377,350

$2,377,350

$2,377,350

$2,377,350

$2,969,831

$2,969,831

$2,969,831

$2,969,831

$2,969,831

Tourism losses
Tax revenue
losses

$0

$0

$0

$0

$0

$9,095,169

$9,095,169

$17,774,561

$9,095,169

$17,774,561

TOTAL

$120,600,299

$140,057,016

$191,275,349

$153,743,646

$224,418,696
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CHAPTER 4 – RVF PREVENTION AND
CONTROL: FARM-LEVEL BARRIERS,
ENABLERS AND WILLINGNESS TO PAY TO
AVOID LOSSES IN CENTRAL SOUTH AFRICA
(AIM 3)
Abstract
Background: Rift Valley Fever presents an economic risk to farms in Sub-Saharan Africa. While
livestock vaccination is the recommended strategy to avoid human and animal outbreaks, uptake
remains limited and inconsistent.
Methods: A survey of commercial farm owners in South Africa’s Free State and Northern Cape
Provinces (n=120) examined barriers and enablers for RVF prevention and control and assessed
willingness to pay (WTP) to avoid damages associated with RVF under varying temporal and risk
scenarios.
Results: 90% of farms were willing to pay something annually to avoid RVF losses; of those,
mean annual WTP to avoid RVF-associated damages was US$808.03 per farm (R11,789.19 at
ZAR14.59=US$1). Higher mean annual WTP for all farms was significantly associated with
higher number of domestic animals and wool farming (p<.05). There was also significant
difference in WTP to vaccinate herds against RVF based on provincial risk (p<.000). Nearly all
farms (89.17%) indicated they would take measures in addition to or instead of vaccination if they
thought risk was high in their province, including insecticide/dip (90.65%) and antibiotics
(28.04%). Only 50.83% and 21.67% thought vaccine supply was sufficient in general and during
an outbreak, respectively. The majority of farms indicated the following factors would make them
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more likely to vaccinate: more rainfall than usual, government subsidy or alert, or vaccine available
locally.
Conclusions: As farm owners are the primary decisionmakers for investment against RVF, our
findings suggest there are opportunities to optimize existing resources to reduce RVF threat via
modifiable practices, risk communication, and supply-side policies.

Introduction
Outbreaks of Rift Valley Fever (RVF) virus in Africa and the Middle East have been associated
with significant animal production and trade losses as well as disease burden and death in humans
via zoonotic disease transmission.1-3 South Africa has experienced several large-scale RVF
epidemics over recent decades, including an outbreak in 2008-2011 resulting in over 300 human
cases and 25 deaths as well as economic impacts to livestock farms estimated at over R300 million
(approximately USD$20.52 million at ZAR14.59=US$1).4-7 In addition, it is suspected that
unreported smaller outbreaks occur during inter-epidemic periods.8
Farmers, veterinarians, and abattoir workers are at elevated risk for RVF infection based on
exposures to infected animals and their products.5,9 While livestock vaccination is the
recommended strategy for prevention of animal and human cases, coverage remains low overall
and inconsistent by year.10 Currently, available livestock vaccines are indicated for annual use,
although some research suggests that prior vaccination or exposure may confer multi-year
immunity.11 As RVF is not a state-controlled disease, decisions made at farm level regarding
vaccine uptake are critical determinants of risk management.12
As livestock constitutes >40% of agricultural gross domestic product in South Africa and
provides important contributions to economic solvency, RVF presents both an economic and
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health risk.13 However, RVF epidemics are not an annual threat, as risk varies based on
environmental and epidemiological factors that affect emergence, circulation, and spread, with
major epidemics occurring every 5-20 years.4,14,15 RVF epidemics are typically associated with
prolonged periods of above-average rainfall (i.e., four months) that allow optimal conditions for
widespread flooding of dambos and subsequent mosquito hatching. This environmental indicator
potentially allows for some lead time for vaccination. However, effectively mobilizing this riskbased strategy would require rapid production and distribution of sufficient stocks of vaccine and
awareness by farmers to promote uptake. In addition, it is suspected that low-level transmission
may occur in inter-epidemic periods and may be missed in the absence of a systematic surveillance
system. For all of these reasons, annual vaccination is generally recommended to maintain a level
of herd immunity and is likely to be the recommended strategy until an adequate risk monitoring
and alert system is in place. Therefore, long-term strategies are needed to optimize resources for
protection against outbreaks and their multi-sectoral damages.16 Understanding the economic
factors that affect demand for RVF prevention and control behaviors can help inform health
security plans and investments.17 This study aimed to identify barriers to and enablers of RVF
vaccine uptake and provide estimates of farm-level willingness to pay to avoid damages from RVF
in central South Africa.

Methods
Data collection: A survey on barriers, enablers and willingness to pay (“WTP”) for RVF
prevention and control measures was administered to farm owners or managers (one per farm) in
the Free State and Northern Cape provinces in the Republic of South Africa between SeptemberDecember 2018. The study region (Figure 3.1) was the center of a large-scale RVF epidemic in
2010-2011. All farms re-enrolling in year five of an existing epidemiological study on RVF
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(n=174) were offered the WTP survey. The original farm recruitment was based on random
selection of geographic points over a 40,000km2 area in central South Africa, with the closest farm
to the coordinate recruited (for additional details, see Msimang et al. 2019).9 Stated WTP was
open-ended, with no anchoring starting value or bidding process (see Appendix for survey
instrument). The survey was conducted in English and provided to farm owners/managers fluent
in English.
Additional survey farm characteristics were collected under a previous survey conducted
between 2015-2017 (using latest data available in our analysis) under the Understanding Rift
Valley Fever Virus in the Republic of South Africa project and merged using a unique farm
identifier. Variables used from this prior survey were selected based on factors that could
plausibility shape farm risk perception, disease management practices, and/or the potential impact
of RVF, including average number of domestic animals (thought to be more valid than the number
of animals present on the farm on the day of the survey, given that number of animals may change
throughout the year due to a farm’s production and sales practices, disease, theft, or other factors),
presence of sheep on the farm, export status, history of disease, environmental attributes (e.g.
presence of dam), and production system type (Table 3.1).
Both surveys were administered via electronic tablet, with responses recorded by a member of
the field team or self-completed by the farm owner/manager. All data were uploaded to an Open
Data Kit application. Number of responses varied by question where participants skipped questions
or gave per-animal instead of per-farm responses.
Ethics: The survey was conducted under the Understanding Rift Valley Fever Virus in the
Republic of South Africa protocol approved by the US Hummingbird Institutional Review Board
(no. 2014–25 24/11/2014), US DTRA Research Oversight Board (CT 2014–33 27/01/2015), SA
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Witwatersrand University Human Ethics Committee (M140306 30/04/2014; 140/2018
11/06/2018), and SA Provincial Departments of Health Free State and Northern Cape. IRB
exemption for secondary data analysis was granted by the City University School of Public Health
Human Subjects Research Program. Enrollment in the survey was voluntary, with informed,
written consent obtained prior to participation. No financial compensation was provided for
participation, and participants were free to skip any survey questions.
Analysis: Descriptive statistics on farm risk management practices and uni- and multi-variate
regression analyses were conducted in STATA/ IC 16.0 (StataCorp, College Station, TX, USA),
using a cutoff value of p <.05 for statistical significance. In total, 124 farms completed the survey
(71% of recruited farms); we restricted our analysis to commercial farms (n=120) given significant
differences in disease management practices and policies between communal and commercial
farming. For WTP measures, participants were asked to state the total amount for their farm that
they would be willing to pay, on the basis of farms having a finite budget for risk management and
the vaccine’s availability in fixed quantities (100 doses per vial). A per-animal estimate of WTP
was also calculated based on reported number of animals on the farm. We excluded one extreme
upper outlier. The primary outcome measure was annual WTP to prevent animal losses from RVF
(“How much would you be willing to pay each year for the next 10 years to prevent animals in
your herd aborting or dying from Rift Valley fever?”). A 10-year time horizon was considered to
be relevant given the sporadic timing of RVF and likely waning attention to the disease between
outbreaks. Linear regression analysis was performed to examine WTP association with farm-level
continuous variables (average number of domestic animals, distance (in km) to an isolated
outbreak in 2018 as a continuous variable given the potential effect of the outbreak on perceived
risk and investment in RVF prevention or control) and categorical variables (export status, sheep
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farming, history of RVF or Brucellosis, vaccination status in past year, on-farm environmental
attributes), with categorical variables coded as dummy variables (e.g., 0 or 1).
To transform farm coordinates from latitude/longitude to a Cartesian coordinate system to
measure farm distance from the 2018 RVF outbreak as a co-variate, we projected farm locations
using the Hartebeesthoek94 Datum projection system (the official geogetic datum for South
Africa) in QGIS version 3.4.15 to convert lat/long values to meters from an origin. To calculate
distance from the farm where the 2018 outbreak of RVF occurred, we used the straight-line
Euclidian distance formula, where x and y are coordinates and i and j represent the survey farm
and outbreak farm, dividing by 100 for kilometers (km):
𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒𝑖𝑗 = √(𝑥𝑖 + 𝑥𝑗 )2 + (𝑦𝑖 + 𝑦𝑗 )2
To assess whether WTP was risk-dependent, we compared WTP for vaccination in low-high risk
scenarios (i.e., if risk of RVF circulating in mosquitoes was low for your province, high for your
province, and high for your farm). Circulation in mosquitoes indicates near-future risk of a health
emergency, when it is not too late to implement prevention measures. A two-sided t-test of means
was conducted to compare WTP from low to high provincial risk and high provincial and farm
risk. All monetary values were converted from South African Rand to US$ using UN Treasury
rates for November 2018 (ZAR14.59= US$1).

Results
Of the 120 commercial farms participating in the survey, the majority (71.16%) were either meat
or meat and wool producers, and 23% were export farms. The average number of domestic animals
per farm varied from 0-11,550, and farm size ranged from 1-13,600 hectares (see Table 3.1 for
farm characteristics).
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Vaccination Practices and Barriers. The majority (62.50%; n=75) of farms stated that they had
vaccinated their herd against RVF within the past year (see Table 3.2). Of the farms that did not
vaccine their animals in the past year (n=45), the main reason stated was perceived risk (“I do not
feel there’s a risk of my farm being infected”) (53.33%). While some farms mentioned cost of
vaccine/lack of finances as both the main and second most important reason for not vaccinating, it
was the main reason for only 22.22% and the second most important reason for only 20% of farms.
Around half (50.83%) felt that supply of the vaccine is sufficient if they wanted to vaccinate their
herd each year; only one-fifth (21.67%) felt that supply is sufficient during an outbreak.
Practices other than Vaccination. Most farms (89.17%) indicated that they would take other
measures (in addition to or instead of vaccination) to avoid impact from the disease if they thought
risk of RVF was high in their province, with 90.65% stating they would use dip (insecticide) and
28.04% would use terramycin (an antibiotic). Additional measures noted by farmers included
moving animals to drier areas/higher elevation and using topical or injectable anti-parasitic (see
Table 3.2 for summary statistics).
Willingness to Pay: Some farms indicated they were not willing to pay anything (i.e., WTP = zero)
to avoid animal losses from RVF. Depending on the scenario, WTP nothing ranged from 5.55% 38.26% of farms (see Figure 3.2). However, even under a low-risk scenario, more than half
(61.74%) indicated they were willing to pay something.
For all farms, mean WTP per farm each year over a period of ten years was R10,610.27
(US$727.23). Estimated per-animal WTP for per year was R33.25 (US$1.96). When restricting to
farms willing to pay something (90% of farms; n=99), mean WTP per farm each year was
R11,789.19 (US$808.03). For farms that said they would use measures instead of or in addition to
vaccination if risk was high in their province, mean WTP was R5,257.98 (US$360.38). For all
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WTP measures, the median value ranged from R2,000-5,000 (US$137-343) (see Figure 3.3 for
distribution of responses by scenario).
When summed, per-year WTP totaled R1,167,130 (US$79,995.20) across the 120 survey farms.
Of the nearly 90% of farms that indicated they would use measures other than or in addition to
vaccination, the amount stated across farms totaled R546,830 (US$37,479.78), or 46.85% of total
per-year WTP stated (see Table 3.3 for additional WTP measures and statistics).
Variables associated with WTP. Higher average number of domestic animals on the farm and being
a wool farm were each significantly associated with higher WTP per year, with each additional
animal associated with R3.83 higher WTP and wool farm status associated with R22,588.17 higher
WTP than non-wool farms (p<.05). Though only marginally significant, the presence of a dam on
the farm also associated with a substantially higher WTP per year of R9,683.30 (p<.10) (see Table
3.4). When controlling for distance from the 2018 outbreak, having any sheep, and reported history
of RVF or Brucellosis on the farm, higher WTP each year to avoid losses from RVF was
significantly associated with higher average number of domestic animals on the farm (p<.000) and
wool farming (p<.05), whereas status as an export farm had a negative association (p<.05) (see
Table 3.5). In the multivariate model, for every additional domestic animal on the farm, adjusted
WTP each year to avoid animal losses from RVF increased by R4.71 when controlling for farm
export status, wool production type, having any sheep, history of RVF or brucellosis, status as a
wool farm, and distance from the outbreak.
Risk difference. When asked about WTP for vaccination of their herd based on perceived risk of
RVF circulating in a mosquito in their province or farm, mean per-farm WTP to vaccinate
against RVF was significantly higher when under the high-risk scenario versus low risk in the
province, with a difference of R3,624.862 (US$248.45) (p.<.001; 95% Confidence Interval: -
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5215.72- -2034.00); this trend was also observed for higher per-farm WTP when risk was high
on farm versus in the province, with a mean difference of R1,614.815 (US$110.68) (p<.001;
96% Confidence Interval: -2495.49- -734.1397).
Potential Vaccination Enablers. The majority of farms stated that the following factors would
make them more likely to vaccinate their herd against Rift Valley fever in any given year: more
rainfall than usual (75.00%), government subsidy for some of the vaccine cost (65.83%), an alert
from the government suggesting higher than normal risk for a Rift Valley fever outbreak (63.33%),
the vaccine being in stock at a local farm supply store (51.67%) (see Figure 3.4).

Discussion
WTP studies on risk management strategies for zoonotic and agricultural diseases are limited in
Sub-Saharan Africa. Our study focused on farm-level economic behaviors, targeting demand by
the key frontline stakeholder influencing RVF risk and impact, including possible areas where
there may be a role for supportive government action. To our knowledge, only one other study has
examined WTP for RVF prevention. Using a double-bounded contingent valuation model with
dichotomous choice amounts, Wanyoike et al. found that WTP for RVF vaccination in Kenyan
cattle producers ranged from a mean of US$1.01-$1.44 per animal depending on predominance of
local versus exotic breeds.18 This is similar to our per-animal annual estimate (US$1.96 per year),
though it represents a larger share of farm resources proportional to the Kenyan economy.
Our results indicate that there is some level of resources available (and cumulatively, a
substantial amount) from the majority of farms surveyed to counter the threat of RVF.
Interestingly, non-vaccination control measures that would be taken under a high provincial risk
scenario comprised nearly half of mean per-farm annual WTP. It is likely that at least some portion
of these other measures are routinely incurred for control of multiple diseases and may not
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represent RVF-specific expenditures. Compared to South Africa’s Gross National Income (GNI)
per capita for 2018 ($5,750), a reasonable wage approximator, average annual WTP represents
nearly 13% of per capita GNI. Given that RVF is one of potentially several diseases that farms
must decide whether or not to invest in vaccination or other prevention or control measures against,
future studies may wish to assess the effect of farm profit margins on WTP to understand whether
relative wealth is an important determinant.
Our multivariate regression analysis showed a significant positive association between WTP
and both the number of domestic animals and wool farming, and a negative association with export
status. More precise examination based on factors such as breed or age of animal, which may affect
retail value, or vaccination practices by species (information which we did not have access to in
the present study) may provide a more detailed understanding of WTP dynamics. While the
number of wool farms in our sample was small (n=4), wool farming had a major effect on WTP,
which may relate to the high losses on the wool industry associated with the 2008-2011 outbreak.19
However, much of the livestock losses seen from the outbreak were attributed to a trade ban placed
on wool and red meat products; therefore, the negative association with export farms is surprising.
It may be explained by products going to the domestic value chain for processing before export,
export farm classification primarily reflecting live animals (potentially with a disincentive to
vaccinate based on inability to differentiate between antibodies from the vaccine and natural
infection), or higher-priority concerns over export restrictions for other agricultural diseases (e.g.
African Swine Fever, Foot and Mouth Disease).
WTP was lower in large-scale cattle producers versus smaller producers in Kenya, likely given
the total per-farm cost implications.18 We therefore believe our primary outcome of WTP per farm
to be a more reliable and policy-relevant measure than WTP per-animal (see Appendix), assuming
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that farm owners face competing budget priorities and consider their aggregate expenditures in
deciding whether to invest in vaccination and/or other RVF prevention and control measures.
Factors affecting candidate animals to be vaccinated in any given year may include species, age,
pregnancy status, holding length, production system, vaccine type, dosage (ewes are vaccinated
twice), and frequency.20,21 Additionally, RVF vaccines are sold in 100-dose vials, representing a
fixed overall cost for farms. Future studies can more directly identify total available farm resources
and share diverted to RVF.
Vaccination rates were considered high in our sample, potentially an effect of heightened
awareness from farm enrollment in a larger RVF study, although previous findings from Kenya
did not observe a significant difference in WTP for vaccination based on awareness about RVF.18
The survey year also had above-average rainfall, with risk alerts issued by the South African
Department of Agriculture (DAFF), and an isolated outbreak was reported on one farm in the Free
State in May 2018 (three months before initiation of our survey).6 These factors likely resulted in
above-average vaccination rates and WTP, although a substantial number of farms that did not
vaccinate cited low perceived risk/drier conditions as the reason, suggesting rainfall levels may
vary between farm and may have influenced risk perception. While we did not find distance from
the 2018 outbreak to be a significant determinant of WTP, there may have been uncertainty about
the outbreak location as the farm name is typically anonymized to district or municipality level
when reporting to the OIE. Additionally, transforming the distance variable from continuous into
categorical (e.g. 0-50, 51-100, 101-150, 151-200km or other increments) could more precisely
examine a potential effect of distance.
We attempted to account for year-to-year variation in underlying risk by asking about average
annual WTP over 10 years. In reality, an optimal vaccination policy likely targets vaccination in
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anticipation of high-risk years (i.e. El Niño cycles with prolonged periods of rainfall) while
maintaining some level of long-term herd immunity.22 Awareness and prioritization of RVF may
decline in the absence of a recent outbreak, resulting in resource allocation changes over time.
Longitudinal studies can capture time- and risk-sensitive trends in WTP.
Vaccine adoption relies on vaccine availability, access, and demand, each component
presenting their own challenges.23 Interestingly, cost was not cited in our survey as the leading
reason for not vaccinating, reinforcing prior findings. Even when RVF vaccine was freely provided
in Kenya and Uganda, uptake was not universal and differed by gender, raising need for gendersensitive considerations ranging from decision autonomy to use of crush infrastructure.24 The
enabling strategies for vaccine uptake identified in our study (i.e., vaccine in stock locally,
government alert or subsidy) may address each of these components.
Our findings are specific to commercial farms in the Free State and Northern Cape provinces,
where the majority of animal losses and human cases occurred in the last major outbreak.5 For
scale, there are an estimated 8,000 commercial sheep farms in the country (mostly concentrated in
the Northern Cape, Eastern Cape, Free State, Western Cape, and Mpumalanga provinces), with
22.6 million sheep as of 2017.25 While context differs from communal farms, there appear to be
some common needs for enhanced risk communication; for example, a recent study by South
Africa’s Agriculture Research Council found awareness of RVF among smallholder farmers in
five provinces to be low, with limited recall of specific symptoms (only 41% of respondents had
knowledge about the disease).26 A prior study found that state-sponsored vaccination was provided
to smallholder farms during the 2008-2011 outbreak;13 therefore, certain farm populations may not
be incentivized to invest in vaccination, or there may be misperceptions about when vaccination
is optimal (e.g. routinely versus during outbreaks).
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While we did not conduct a comprehensive knowledge, attitudes and practices study, our
findings suggest deficits in use of appropriate risk reduction measures. The dip/insecticide
products that were commonly cited by farmers as countermeasures they would use against RVF
were not labeled specifically for mosquito control and included pyrethrins and pyrethroids,
organophosphors, and carbamates, which can be toxic for humans and wildlife (see Appendix).
Additionally, a previous study found that 6% of farmers reported using terramycin (which contains
the antibiotic oxytetracycline) during the 2008-2011 RVF epidemic.7 Our finding that nearly 30%
would use an antibiotic, as well as some farmers indicating they would use topical or injectable
antiparasitic, both which are ineffective against RVF virus, is concerning. Information targeted to
effective measures against viral threats may help avoid wasteful spending and reduce negative
externalities (e.g. risk of antimicrobial resistance from unnecessary antibiotic use) (see Table 3.6).
These are in addition to other issues raised previously for RVF vaccination, including risk of
inadvertent spread of RVF if needles are reused for vaccination (especially during outbreaks) and
spoilage without sufficient cold chain.13,27 Only 67% of South Africa’s rural population, where
livestock production activities are concentrated, has access to electricity, presenting logistical
challenges for cold storage.28 Solutions such as joint human and livestock vaccination campaigns
have been explored for deploying cold-stored vaccines in remote settings without access to
refrigeration, e.g. nomadic herders in Chad.29 Further research could examine South Africaspecific strategies such as animal health extension services, information alerts, or cold storage
labelling as ‘nudges’ for effective vaccination strategies.
Benefit framing has been shown to influence WTP, with respondents potentially assigning
widely different WTP values for related interventions based on different stated benefits.30
Identifying the value-add for farm owners may help inform marketing strategies to encourage
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vaccine uptake. Bundling interventions may be productive for multiple animal health
enhancements. In the long term, technology development may offer new cost-effective solutions,
as demonstrated recently for a 2-in-1 cattle vaccine under development that is protective against
Lumpy Skin Disease, a common agricultural disease typically seen annually in the country, and
RVF.10,31 RVF vaccine supply challenges are not limited to South Africa;32,33 other initiatives have
raised the idea of regional RVF vaccines stockpiles.20 South Africa’s production likely offers
efficiencies for responding to demand; to address supply issues, improving coordination between
the producer and farm stores to ensure stocks are monitored, or alerting farms that they can order
vaccines from the producer, may increase farmer confidence at low cost.
Different WTP measures have been found to yield different results, and contingent valuation
(and potentially other) measures may be highly income-sensitive.34 In designing our study, we
used prior findings from farmer spending in South Africa as a proxy for revealed preferences to
identify cost items and options to frame our measures around.7 We focused on avoidance of losses
rather than generation of gains,35,36 using an open-ended WTP to reduce potential for anchoring
bias. While knowledge of vaccine pricing may still have influenced farmers’ estimate, it is unlikely
it would be a limiting factor; for example, as Wanyoike et al. report, the Kenyan populations
surveyed had previously paid for RVF vaccination services from the government and valued
vaccination above that amount.18 Our sample was not normally distributed, even when restricting
to those willing to pay anything; although outliers skewed the mean upwards, they were largely
consistent across WTP measures. Scatterplots of WTP compared to each variable could be
valuable to help visualize and account for other variation and may suggest stronger linear
associations if log-transformed.
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Pairing farm-level findings with WTP for RVF prevention and control by other stakeholders
(e.g. provincial and national government, donors) can help assess resource allocation options based
on WTP shortfalls and resource efficiency. Cost-benefit analyses should take into account the
potential externalities that can be derived from RVF prevention, including public and animal health
and economic protection at national and international levels (Table 3.6).37-40 This societal view can
help optimize the multi-sectoral utility of private and public spending.17
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Figure 3.1 Map of study area, depicting South Africa and study provinces in yellow.

Table 3.1 Characteristics of the 120 commercial farms surveyed.

91

Categorical
Variables

Continuous

% of
Number
farms

Farm type
Commercial

120

Domestic animals

120

Domestic + wild animal
farming
Any sheep on farm
Export status
Export farm
Disease history
History of Brucellosis or
RVF
Farm production type
Dairy
Meat
Meat + Wool
Wool
Resale
Tourism
Environmental
Attributes
River present on farm
Pan present on farm
Dam present on farm

3
92
27

Variables

Number of hectares
Distance from 2018
100%
outbreak (km)
Average number of
100%
domestic animals
3% Number of cattle
77% Number of goats
Number of sheep
23% Number of springbok
Number of kudu

32

27% Number of blesbok

3
65
30
4
14
2

Number of pigs
3%
Total number of
55%
domestic animals (all)
25%
3%
12%
2%

32
54
100

Mean

Range

2,376

0-13,600

112

9-195

979

0-11,550

190

0-3,000

8
774
36
1

0-342
0-11,400
0-2,050
0-40

10

0-100

2

0-180

115,572
(all farms)

27%
45%
83%
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Figure 3.2 Farms willing to pay something versus nothing to avoid losses from RVF under different
scenarios.

Willing to Pay Something, by Scenario
100%
90%

Percentage of farms

80%
70%
60%
50%
40%
30%
20%
10%
0%

Each year for
10 years

Risk low in Risk high in
province
province
Scenario

WTP something

Risk high on
farm

WTP nothing
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Table 3.2 Farm behaviors regarding RVF prevention and control.
Variable
Number
Other measures (in addition to/instead of vaccination) if RVF risk high in province
Would take other measures
107
Other measures farms would take:
Dip
97
Terramycin
30
Other*
20
Other: moving animals to higher ground/drier areas
10
Other: injectable or topical antiparasitic
7

Percent of farms
89.17%
90.65%
28.04%
18.69
9.35%
6.54%

Vaccination against RVF
Vaccinated within past year
75
62.50%
Primary reason for not vaccinating in past year:
Do not feel there’s a risk of farm being infected
24
53.33%
Cost/lack of finances available
10
22.22%
No protection
1
2.22%
Other**
10
22.22%
Second most important reason for not vaccinating in past year:
Cost/lack of finances available
9
20.00%
Not required
8
17.78
Do not feel there’s a risk of farm being infected
6
13.33%
Time
6
13.33%
No protection
2
4.44%
Other**
14
31.11%
Factors making farm more likely to vaccinate
More rainfall than usual
90
75.00%
Government subsidizes vaccine
79
65.83%
Alert from government
76
63.33%
Vaccine in stock at local farm supply store
62
51.67%
Neighbor vaccinates
35
29.17%
Vaccine supply
Sufficient in general
61
50.83%
Sufficient during outbreak
26
21.67%
*Categories under “Other” were grouped post-survey from open-ended responses; therefore, it is possible
additional farms may undertake these practices.
**Among other primary reasons cited for not vaccinating were time, lack of vaccine availability, dry conditions,
farm has wildlife only or a closed herd; and safety concerns over animal pregnancy status.
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Table 3.3 Reported WTP by measure, in South African Rand and US Dollar
All Farms
Measure

Each year
for 10 years
Risk low in
province
Risk high in
province
Risk high on
farm
Other RVF
Prevention
Measures*

Mean

Median

Range

Farms WTP>0
Mean
Standard
PerMean
Dev.
animal
South African Rand (ZAR)

Median

Range

Standard
Dev.

10,610.27

4,500

0-100,000

20,157.14

33.25

11,789.19

5,000

150-100,000

20,925.49

5,350

1,000

0-100,000

13,817.93

11.18

8,665.49

4,000

150-100,000

16,787.22

9,260.18

5,000

0-100,000

15,661.90

30.44

9,895.69

5,000

150-100,000

15,998.27

10,891.30

5,000

0-100,000

16,312.31

42.93

11,531.96

5,000

150-100,000

16,566.16

5,257.98

2,000

0-100,000

11,808.51

16.48**

5,309.03

2,000

0-100,000

11,854.72

USD ($)
Each year
for 10 years
Risk low in
province
Risk high in
province
Risk high on
farm
Other RVF
Prevention
Measures*

727.23

308

0-6854.01

1,381.57

1.96

808.03

343

367

69

0-6854.01

947.08

0.77

593.93

274

634.69

343

0-6854.01

1,073.47

2.09

678.25

343

746.49

343

0-6854.01

1,118.05

2.94

790.40

343

360.38

137

0-6854.01

809.36

1.13**

363.88

137

10.286,854.01
10.286,854.01
10.286,854.01
10.286,854.01
0-6854.01

1,434.24
1,150.60
1,096.52
1,135.45
812.52

*Already restricted to those indicating they would take other control measures in addition to/instead of vaccination.
**Provided directly by survey participants (for other measures, per-animal WTP was calculated by the authors using
average number of domestic animals on farm).
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Figure 3.3 Whisker plot displaying distribution of WTP responses. Note: one outlier (WTP= R200,000)
was previously removed from the dataset.
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Table 3.4 Univariate regression analysis for WTP each year to avoid animal losses from RVF.
Variable
Any Sheep on Farm

Coefficient Std. Err.

P>t

-2061.639

4540.316

0.651

2765.844

4334.451

0.525

3.828362

1.183716

0.002

Distance from 2018 outbreak

-8.758225

42.71315

0.838

Export farm

-3402.674

4663.413

0.467

Size of farm

0.9885739 0.7318296

0.180

Pan on farm

-2849.794

3922.097

0.469

Dam on farm

9683.298

5772.658

0.096

-798.3061

4138.916

0.847

22588.17

10155.8

0.028

Meat + Wool farm

-6264.554

4612.217

0.177

Dairy farm

-9983.302

14522.17

0.493

Resale farm
* p<0.05

-7525.365

5795.77

0.197

Prior RVF or Brucellosis on Farm
Average Number of Domestic
Animals*

Spring on farm
Wool farm*

Table 3.5 Multivariate regression analysis for WTP each year to avoid animal losses from RVF.
WTP Each Year
Coefficient Std. Err.
t
P>t
[95% Conf. Interval]
Average Number of Domestic
Animals*
4.71
1.304759
3.61 0.000 2.123862
7.302366
Any Sheep on Farm
-5456.59
4795.923 -1.14 0.258 14973.95
4060.762
Distance from 2018 Outbreak
-38.20
43.14156 -0.89 0.378 123.8156
47.41044
History of RVF or
Brucellosis on Farm
2144.02
4233.144
0.51 0.614 6256.516
10544.56
Export Farm*
-10363.36
5106.939 -2.03 0.045 20497.92 -228.8086
Wool Farm*
21982.70
10401.57
2.11 0.037 1341.127
42624.28
Constant
15552.95
6527.363
2.38 0.019 2599.611
28506.29
* p<0.05
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Figure 3.4 Farms selecting factors that would increase likelihood of vaccination against RVF (“select all
that apply”)
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Table 3.6 Examples of benefits and costs associated with vaccine prevention of Rift Valley Fever, with
scale of benefits derived. Strategies are considered net beneficial if benefit exceeds cost. Adapted from
Jeuland et al. 2009.
Benefit delivered
Private (Farm)
Externality 1
(Farm-Proximal)
Externality 2
(Local/National)
Externality 3
(Local/National)
Externality 4
(National)
Externality 5
(National)
Externality 6
(International)

Cost incurred
Benefits to vaccinated animals
Herd immunity in animals

Vaccine purchase

Health and productivity savings to health and labor
sectors from averted cases (avoided illness/death)
Health and productivity savings to livestock sector from
averted cases (e.g. avoided value chain disruption,
restocking)

Vaccine delivery
(awareness raising,
cold chain, wastage,
time opportunity cost)

Protection of international trade status

Surveillance and other
risk monitoring (e.g.
weather projections)

Protection of domestic market confidence
Risk communication
Avoided cross-border disease introduction

99

STATA Syntax:

graph box WTP_EachYear WTP_RiskLowProvince WTPRiskHighProvince
WTPRiskHighFarm WTP_OtherMeasures_FarmQ4
summarize WTP_EachYear, detail
summarize WTP_EachYear_PA, detail
summarize WTP_EachYear if WTP_EachYear>0, detail
summarize WTP_RiskLowProvince, detail
summarize WTPLowRiskProv_PA, detail
summarize WTP_RiskLowProvince if WTP_RiskLowProvince>0, detail
summarize WTP_ WTPRiskHighProvince, detail
summarize WTPRiskHighProv_PA, detail
summarize WTP_R WTPRiskHighProvince if WTPRiskHighProvince>0, detail
summarize WTP_WTPRiskHighFarm, detail
summarize WTPRiskHighFarm_PA, detail
summarize WTP_WTPRiskHighFarm if WTPRiskHighFarm>0, detail
summarize WTP_OtherMeasures_FarmQ4, detail
summarize WTP_OtherMeasures_AnimalQ4, detail
total WTP_EachYear
total WTP_OtherMeasures_FarmQ4
graph bar w7vac_more_likely_rain w7vac_more_likely_gov
w7vac_more_likely_al w7vac_more_likely_stock w7vac_more_likely_neigh
ttest WTP_RiskLowProvince= WTPRiskHighProvince
Paired t test
Variable

Obs

Mean

Std. Err.

Std. Dev.

[95% Conf. Interval]

WTP_Ri~e
WTPRis~e

109
109

5635.321
9260.183

1354.436
1500.138

14140.73
15661.9

2950.594
6286.65

8320.048
12233.72

diff
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-3624.862

802.5837

8379.22

-5215.722

-2034.002

mean(diff) = mean(WTP_RiskLowPro~e - WTPRiskHighPro~e)
t = -4.5165
Ho: mean(diff) = 0
degrees of freedom =
108
Ha: mean(diff) < 0
Pr(T < t) = 0.0000

Ha: mean(diff) != 0
Pr(T > t) = 0.0000

Ha: mean(diff) > 0
Pr(T > t) = 1.0000

ttest WTPRiskHighProvince= WTPRiskHighFarm
Paired t test
Variable

Obs

Mean

Std. Err.

Std. Dev.

[95% Conf. Interval]

100

WTPRis~e
WTPRis~m

108
108

9276.481
10891.3

1514.004
1569.653

15733.99
16312.31

6275.146
7779.643

12277.82
14002.95

diff

108

-1614.815

444.2506

4616.788

-2495.49

-734.1397

mean(diff) = mean(WTPRiskHighPro~e - WTPRiskHighFarm)
t = -3.6349
Ho: mean(diff) = 0
degrees of freedom =
107
Ha: mean(diff) < 0
Pr(T < t) = 0.0002

Ha: mean(diff) != 0
Pr(T > t) = 0.0004

Ha: mean(diff) > 0
Pr(T > t) = 0.9998

Correlation
*assessing correlation in multivariate model variables*
corr WTP_EachYear FNL_TotalPopDomR_Ave AnySheep Distance2018Outbreak DiseaseEver
ExportStatus Wool (obs=105)
Raw STATA output (coded variable names):
WTP_Ea~r

FNL_To~e

AnySheep

Distan~k

Diseas~r

Export~s

WTP_EachYear

1

FNL_TotalP~e

0.2921

1

AnySheep

-0.0497

0.2467

1

Distance20~k

-0.0276

0.1465

-0.0609

1

0.0545

-0.0604

0.1037

-0.161

1

-0.0706

0.3612

0.2883

0.1376

-0.0399

1

0.2099

0.2164

0.1083

0.1617

0.0893

0.2555

DiseaseEver
ExportStatus
Wool

Wool

1

STATA output updated (coded variable names replaced with explained variable names):
WTP Each
Year
WTP
EachYear
Ave. #
Domestic
Animals
Any Sheep
on Farm
Distance
from 2018
Outbreak
RVF or
Brucellosis
in Past
Export Farm
Wool Farm

Ave. #
Domestic
Animals

Any
Sheep
on Farm

Distance
from 2018
Outbreak

RVF or
Brucell
osis in
Past

Export
Farm

Wool
Farm

1
0.2555

1

1
0.2921

1

-0.0497

0.2467

1

-0.0276

0.1465

-0.0609

1

0.0545
-0.0706
0.2099

-0.0604
0.3612
0.2164

0.1037
0.2883
0.1083

-0.161
0.1376
0.1617

1
-0.0399
0.0893
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CHAPTER 5 – CONCLUSION
Local and global health security relies on effective measures to prevent, detect, and respond to
biothreats.1,2 For zoonotic and vector-borne infectious diseases such as Rift Valley Fever, the close
association with environmental and animal factors requires enhanced engagement of multiple
sectors to target risks and impacts, especially in light of changing climate, demography, livestock
production systems, and mobility.3 This dissertation applies a One Health approach to RVF to
estimate health burden and identify reporting gaps across species, assess its societal costs, and
generate ideas for optimizing practices and investments to improve disease management. In
particular, this information provides insight on how One Health strategies can be taken up by
multiple stakeholders, including areas where government and development funders can
supplement private sector actions.

Summary of results
Collectively, the findings of this dissertation demonstrate that Rift Valley Fever is a persistent
biological threat with under-reported consequences to humans, animals, and economies. Our
results, synthesized below by Aim, provide multisectoral estimates of RVF impacts at global and
national (South Africa) level, paired with analysis farm-level economic behaviors of the primary
decision maker for RVF prevention and control to examine complementary multi-scale and
stakeholder implications. Our findings can serve as a basis for future cost-benefit analyses at
regional, national or local level to assess optimal investments in prevention and control.
Aim 1
In Aim 1, we compiled reports of animal and human disease and deaths from RVF. Between 20002019, RVF was reported in 32 countries, 22 of which reported both animal and human cases. 5,228
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suspected human cases and 987 deaths, along with 72,960 animal cases and 17,810 animal deaths,
were attributable to RVF via official reporting sources. Logistic regression for country reporting
of RVF development-relevant predictor variables indicated that publication bias was positively
associated with RVF reporting, whereas odds of reporting RVF were lower in countries with higher
level of political stability and absence of violence and higher percentage of population with access
to electricity (p<.05), partially supporting our hypothesis that RVF disproportionately causes
disease burden in least- compared to most-developed countries while suggesting strong effect of
surveillance bias. However, given limited available data, we did not analyze whether there was a
relationship between burden (via number of cases or deaths) and country variables. On average,
countries reporting RVF in Africa have high dependence on livestock, and face major economic,
infrastructure, and capacity deficits, which can be expected to affect implementation and efficacy
of RVF prevention, detection and response programs.
Aim 2
We analyzed the societal cost associated with RVF in South Africa between 2003-2018. RVF was
associated with at least US$120.6 million in expenditures and losses, the majority of which were
incurred during epidemic periods. This minimum estimate is 3.3 times the prior estimate of farmlevel livestock losses in the country. We identified tangible losses in the health, agriculture,
environment, and financial sectors. The burden of disease from RVF was estimated at 680.913
Disability-Adjusted Life Years, with the majority from premature death. Our findings are in
support of our hypothesis 2a that economic impacts of RVF disproportionately affect non-health
sectors compared to health sectors. Costs were concentrated in the livestock sector (particularly
via post-farm value chain and exports) (85.5%), tax revenue (7.5%), and wildlife products (2.5%).
Productivity losses and medical and public health spending accounted for approximately 4.5% of
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total costs. The majority of costs were incurred for response versus prevention, supporting
hypothesis 2b.
Aim 3
In Aim 3, 90% of farms in our sample of 120 commercial livestock farms in South Africa’s Free
State and Northern Cape provinces were willing to pay something annually to avoid RVF losses,
with an overall mean of $727.23 per year. Higher mean annual WTP to avoid animal losses from
RVF was significantly associated with higher number of domestic animals and wool farming
(p<.05). There was also significant difference in WTP to vaccinate herds against RVF based on
level of risk of RVF circulating in mosquitoes in their province or on their farm (p<.000),
supporting our hypothesis that WTP for vaccination rises with increased risk. Most farms indicated
they would take measures other than or in addition to vaccination if they thought risk of RVF was
high in their province, including insecticide/dip (90.65%) and antibiotics (28.04%). Several
barriers and enablers were identified for uptake of livestock vaccination against RVF; among
barriers, approximately half the farms thought vaccine supply was sufficient in general, whereas
less than one-fourth thought it was sufficient during an outbreak. For those that had not vaccinated
in the past year, cost was not the most common primary reason, though most farms cited different
primary and secondary reasons for not vaccinating, suggesting that there are multiple impediments
to vaccine uptake. Higher rainfall than normal, government risk alert, subsidization, and vaccine
in supply at local farm store were all factors that would increase likelihood of vaccination
identified by at least half of the respondent farms.

Policy implications and research opportunities
The need for a One Health approach is articulated under the Global Health Security Agenda
Roadmap to 2024, alongside a call for advancing sustainable financing for health security.4 Our

107

national cost analysis and farm-level study showcases how applying a One Health lens can more
comprehensively capture societal impacts of zoonotic diseases than single-sector analyses alone.
This information can be useful for design of National Action Plans for Health Security, regional
and global disease control programs, and ultimately budget allocations to optimize resources.
While financial support mobilized from the Coalition for Epidemic Preparedness and its
partners offer needed advancements in human RVF vaccine candidates, it is also important that
efforts attend to the populations most directly vulnerable to RVF risk and impacts, particularly
those with high dependence on livestock. Prior studies have framed issues with animal vaccine
adoption for smallholder and marginalized populations in terms of availability, access, and
demand, which our findings shed further light on:5
Availability: The widescale under-reporting for both animal and human disease burden via official
sources is likely to hinder sufficient targeting of vaccines to areas that need them. In our study in
South Africa, a country where RVF vaccines are produced, farmers reported supply issues that are
probably indicative of larger regional vaccine availability issues. Several vaccines are available,
each with different use requirements and timing; therefore, vaccination strategies will likely have
to be paired with outreach to ensure effective and safe use.6
Access: Economic and infrastructure constraints are likely to present issues in terms of
affordability and dissemination to rural communities. Country development indicators (and ideally
downscaled information where available) is useful for identifying the contexts where potential
interventions will be deployed, and likely provide logistical indication of the reasons for failure or
limitations of past programs. For example, that countries reporting RVF in the past two decades
have an average of 32% electricity coverage suggests vaccination campaigns in their current form
are unlikely to be successfully sustained if reliant on a cold-stored vaccine, particularly for
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countries dependent on imported vaccines. In Sub-Saharan Africa, the literacy rate was only 67%
as of 2018; therefore, risk communication and vaccine instruction must be delivered in ways that
meaningfully serve communities at risk, including those with low existing awareness and
alternative belief systems about causes of livestock disease.7-9 Even with 100% efficacy,
vaccination campaigns will have to be strategically deployed to ensure their effectiveness (i.e. for
“real world” outcomes).10
Demand: Vaccination sales data indicates inconsistent demand from year-to-year, with demand
rising in epidemic periods. We also find that risk perception, a factor in demand, may be nuanced.
Our willingness to pay survey was conducted in 2018, when there was above-average rainfall after
a multi-year drought with associated increase in mosquito activity, the government had issued a
risk alert, and there had been an isolated outbreak on one farm earlier that year. However, while
overall vaccination rates in our survey were considered high, lack of risk or related reason such as
dry conditions together were most commonly described as the primary reason for those that did
not vaccinate. This suggests that even in high-risk years, perceived risk may be variable across
individual provinces, which may result in varying vaccine demand among farms. Pairing remote
sensing data with field-based environmental studies may help to assess local variability in rainfall
levels for more granular understanding and predictability across farms. This gives some indication
that our risk scenarios using mosquitoes was correctly targeted to an indicator they would likely
be sensitive to; however, if rainfall is an indication, it also suggests that mosquito presence is not
uniform across farms. Still, on a population level, improved risk models that provide lead time for
upscaled vaccine production and administration may aide governments and the private sector in
addressing availability, access and demand issues more proactively.11,12
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Our study adds to the limited evidence base using WTP as a measure of resource availability
for zoonotic disease prevention and control.13-16 For some research questions, alternate methods to
elicit preference and behavioral information, such as “willingness to accept”, may be more
appropriate.17 For example, concerns expressed by farmers about safety of the vaccine may require
perceived or real tradeoffs by farmers to vaccinate; industry offerings such as RVF-free
certification may also come at a buy-in cost for farmers in which acceptance of the conditions (e.g.
cost or potential requirements such as inspection or vaccination) is implicit. Economic studies can
enhance market responses for push and pull mechanisms to encourage and sustain vaccine uptake.
Government policy measures such as compensation to farms for animal losses may play a role in
mitigating disease impacts;18,19 however, there may be heterogeneity in livestock keepers in terms
of non-economic factors (e.g. risk attitudes, production types and species) influencing acceptance
of compensation for behavior change.20 Framing questions around “willingness to contribute” to
surveillance systems and disease control may also target non-monetary barriers to increase
community participation and may potentially raise awareness around the positive externalities of
farm-level practices.21 Future measures can also allow for more precise estimation of RVF-specific
measures (versus measures such as dipping that may be applied for control of multiple diseases)
and determine amount in relation to total farm budget.
Recent reviews have called for the need to improve zoonotic disease surveillance, laboratory
testing, and information sharing partnerships to enhance global health security.22 Country-level
prioritization of endemic and emerging zoonoses is a key tool for developing concerted disease
control programs and setting shared objectives for human and animal health and environment
sectors.23 Addressing the chronic issue of under-reporting and misdiagnosis of RVF will help to
better target such strategies and generate greater awareness and support the importance of
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investments in prevention. The limited disease awareness and diagnostic capability issues are
common to other neglected zoonotic diseases, including those with similar livestock-related
exposure pathways and clinical outcomes, such as brucellosis.24
In addition to disease-specific risk factors, the importance of considering the broader
development context was recently highlighted for reducing global antimicrobial resistance and
served as the motivation for our univariate analysis of country development factors associated with
RVF reporting.25 This approach has several practical applications, including in assessing vaccine
access barriers as discussed above. At present, zoonotic disease risks are not currently routinely
considered in safeguard and impact assessment processes associated with economic development
projects.26 Introduction of irrigation systems, for example, have been associated with increased
exposure to RVF and other vector-borne diseases, including in South Africa.27-29 The development
characteristics of countries and communities reporting RVF (e.g. on veterinarian access,
dependence on livestock for income and protein supply, electricity coverage) can provide at least
broad indications of economic and infrastructure factors to consider when designing livestock and
other agricultural investments in areas at risk for RVF. Considering these limitations prospectively
may better anticipate risks and allow for mitigation strategies to be built in from the onset.
Similarly, areas at risk for RVF and other environmentally-sensitive diseases (e.g. leptospirosis)
anticipated to see increased rainfall and vector suitability with climate change should ensure that
RVF is considered in differential diagnoses, diagnostic capabilities, and community awareness as
part of preparedness measures for climate-smart healthcare and public health delivery.30,31
Vaccination of RVF is considered to generate positive externalities in the form of protective
immunity, reduced potential for disease spread, and avoided losses relevant to animal production,
public health, and other sectors. Our results indicate that some measures that farmers would take
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to counter RVF may actually yield negative externalities (e.g. unnecessary antibiotic and
antiparasitic use). Here, government veterinary services can provide a key low-cost intervention
to improve farmer awareness of appropriate control measures for multiple disease threats. Finally,
the broad factors and trends affecting the trajectory of RVF each warrant greater attention and
should be considered in the context of overall risk as well as novel partnerships. Currently, there
is no long-term prevention or control strategy for RVF at global or national levels that takes these
multifactorial determinants of RVF risk into account, leaving human and animal populations
vulnerable to the threat of RVF and missing key opportunities for synergies in research, monitoring
and investments.

Key strengths
This dissertation is unique in applying a One Health perspective to more comprehensively estimate
the impacts of RVF. This approach is valuable for quantifying the societal implications of disease,
including both direct and indirect costs, and identifying potential cumulative, society-wide benefits
of prevention and control, helping to identify more relevant cost-effectiveness thresholds for
intervention strategies. In addition, it can help to identify relevant stakeholders that may be
incentivized to contribute to reducing risk and impacts of the disease. We present practical,
reproducible methods that can be readily adapted for other diseases or country contexts. Our
approach lends itself to a case study on the intersections between disciplines for health security
gains and the ways in which Planetary Health research and policy questions can contribute to the
Sustainable Development Agenda.
Our focus on RVF impacts and prevention and control investments in South Africa in Aim 23 allowed for detailed understanding of the specific country context for RVF. Particularly for
domestic policy and financing decisions, this detail is likely necessary to engage stakeholders,
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identify relevant impacts, and identify effective and feasible intervention strategies. Taken
together, they provide a coherent foundation that can be directly utilized in cost-benefit analyses
and to inform national, provincial and industry-level policy making across different payer groups.
The involvement of South African researchers as well as a range of national partner and
stakeholder institutions was critical for the validity and depth of the inputs, assumptions, and
parameters in our impact analysis.

Limitations
Specific limitations of our studies are highlighted in chapters 2-4. Overall, the main limitations
relate to poor information availability, recall and response bias, and generalizability of our
findings.
In Aim 1, the reliance on official sources for our base estimate demonstrated clear reporting
gaps. We could not verify consistency of case or outbreak definitions by country and reporting
source. We assessed RVF and country-level predictors, but these factors may manifest in more
nuanced ways, especially for the subsets of populations most vulnerable to RVF exposure and
impacts (i.e., rural populations with greatest dependent on their livestock and likely with
disproportionately lower income, electricity access, healthcare services availability, and other
relevant socio-economic disparities). Similarly, our multi-sectoral, multi-year analysis in Aim 2
depended on metrics from different sectors, sources, years (2003-2018), and currencies (South
African Rand and US$). For the latter, there are several ways to adjust for inflation and convert
currency, potentially yielding variable results.32 As a key intended outcome was to deliver an
analysis that could be directly useful for South African stakeholders (i.e., with a version in Rand),
we based our analysis off of mostly nominal costs recorded for each year and adjusted for inflation
prior to converting to US% to estimate real costs (the one exception was productivity estimates,
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which were supplied in US$ at current value). However, estimates may vary if alternate exchange
or inflation practices are used. The value of the Rand weakened during the 15-year time period,
which may have an effect on buying power relevant to RVF prevention and control (e.g., for
imported diagnostic reagents) not captured in our analysis.
In Aim 3, our findings provide the first estimates from South Africa for WTP to avoid losses
from RVF and identify several farm-level barriers and potential enablers for RVF vaccination.
However, they should be interpreted with several caveats. First, it was not possible to pilot our
survey instrument prior to use, and it is unclear how sensitive the questions were to the different
scenarios provided. Second, the farms recruited for the survey likely had higher awareness around
RVF than the overall farm population in the provinces simply as a result of their participation in a
larger 5-year RVF study. While it is probable that they may ascribe higher priority to RVF
prevention and control as a result, it is also plausible that they felt compelled to state higher WTP
amounts than they actually would be willing to pay (i.e., response bias), skewing stated WTP
upwards. Ideally, future studies can avoid this potential source of bias through anonymous surveys;
however, this may be logistically challenging in certain settings (e.g. areas without reliable mail
systems or in populations with low literacy levels). Third, we assumed that our question on WTP
each year for a period of 10 years was generally indicative of annual WTP indefinitely, and broadly
representative of an average time frame between RVF outbreaks. However, the variability of WTP
during different risk scenarios suggests annual WTP would not be constant. This is supported by
the low level of investment seen in inter-epidemic periods via vaccine sales data reported in Aim
2 (chapter 3).
For Aims 2-3, our findings are specific to South Africa; however, given South Africa’s relative
wealth and strong public and animal health expertise, our findings are likely to be indicative about
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broad deficits in capacity and investment to counter RVF, which are likely more severe in other
countries across the continent. In Aim 3, we did not include communal farms in analysis, which
comprise the majority of farmers in some regions of South Africa (e.g. KwaZulu-Natal). Similarly,
the severity of the 2008-2011 outbreak in the Free State and Northern Cape, as well as the isolated
outbreak in 2018, may result in farmers ascribing greater priority to the disease than elsewhere in
the country. Therefore, our findings are most appropriate for informing targeted management
strategies for private farmers in the two provinces but may be poorly indicative to other production
systems and provinces, as well as for other countries where pastoralist herding systems may have
unique implications for disease risk and management practices. For example, a study of RVF
knowledge and practices in nomadic livestock herders in Nigeria found that use of vector repellent
was limited (<40% of farmers compared to the majority of farmers in our study).33 Similarly,
different regulations on insecticide use, as well as resistance, may influence availability of nonvaccination options for vector control.34
Finally, while not specifically a limitation, it should be made explicit that our lens for viewing
RVF impacts was consistent with welfare analysis and the intent to maximize provision of public
goods (i.e., good animal and human health and their resulting gains and avoided losses).35,36 We
did not seek to assess net effects via general equilibrium models to fully account for market shocks
and rebounds over time via national income or social accounting matrices. Therefore, our findings
may not be directly comparable with certain types of impact estimates.

Overall Conclusions and Future Directions
RVF and other environmentally-sensitive zoonotic and agricultural disease warrant attention in the
context of climate change, food security, and cross-border disease risks. Our findings serve as a
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basis for interventions, including some low-cost supportive risk communication and other
supportive policies. This is a major need for RVF and other zoonotic disease to identify appropriate
solutions, particularly as RVF has largely occurred in low-resource settings where overall public
health and veterinary resources are limited. While we do not compare our findings against impacts
of other diseases to determine relative significance of RVF, ideally interventions can be developed
with multi-disease prevention in mind to optimize benefits and promote overall preparedness.
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APPENDIX
Aim 1. Animal and human disease reporting
Distribution by species
Figure A1.1 Animal cases and deaths reported to OIE by species (distribution shown by year).
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By country
Table A1.1 Reporting by country (animal, human, both, or neither) (1=reported).
Animal
Report
Middle East and North Africa
Algeria
Bahrain
Djibouti
Egypt, Arab Rep.
1
Iran, Islamic Rep.
Iraq
Israel
Jordan
Kuwait
Lebanon
Libya
Malta
Morocco
Oman
Qatar
Saudi Arabia
1
Syrian Arab Republic
Tunisia
United Arab Emirates
West Bank and Gaza
Western Saharan
Yemen, Rep.
1
Sub-Saharan Africa
Angola
Benin
Botswana
1
Burkina Faso
Burundi
Cabo Verde
Cameroon
1
Central African
Republic
1
Chad
1
Comoros
1
Congo, Dem. Rep.
1
Congo, Rep.
Cote d'Ivoire
Equatorial Guinea
Eritrea
Eswatini
1
Country

Human
Report

Both

Neither

Animal OR
Human

1
1
1
1

1
1
1
1
1
1
1
1
1
1
1
1

1

1
1
1
1
1
1

1

1

1

1
1
1
1

1

1
1

1

1

1

1

1

1

1
1
1
1
1
1
1
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Ethiopia
Gabon
Gambia, The
Ghana
Guinea
Guinea-Bissau
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mauritius
Mayotte
Mozambique
Namibia
Niger
Nigeria
Rwanda
Sao Tome and Principe
Senegal
Seychelles
Sierra Leone
Somalia
South Africa
South Sudan
Sudan
Tanzania
Togo
Uganda
Zambia
Zimbabwe
Total

1

1
1

1

1

1
1

1

1
1

1

1

1
1
1

1

1

1
1

1
1

1
1

1
1

1
1
1
1

1

1

1
1

1
1

1

1

1

1

1

1

1
1

1
1
1
1
1
1
1
1

1
1
1
1
1

1
1
1
1

1

1

1

1

1
29

1
25

1
22

1
1
39

10
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Aim 2: cost calculations
METHODS

Adjusting for Inflation
We calculated impacts using nominal and inflation -adjusted values. We used consumer price
index (2010 = 100) compiled by the International Monetary Fund
(https://data.worldbank.org/indicator/FP.CPI.TOTL?locations=ZA) to convert nominal values to
real values up to 2018 using the adjustment formula:
𝐶𝑎𝑑𝑗𝑢𝑠𝑡𝑒𝑑 = 𝐶𝑛𝑜𝑚𝑖𝑛𝑎𝑙 (

𝐶𝑃𝐼2018
𝐶𝑃𝐼𝑦

)

Where: 2018 is the reference year and y is the year for adjustment.
Table A2.1 Consumer price index (2010 = 100)– South Africa. Source: The International
Monetary Fund
(https://data.worldbank.org/indicator/FP.CPI.TOTL.ZG?locations=ZA).
2003

2004

2005

2006

2007

2008

2009

2010

73.2629275

72.7559259

74.2567732

76.6655899

81.4018459

89.5870311

96.0951367

100

2011

2012

2013

2014

2015

2016

2017

2018

105.017158

111.028281

117.441723

124.647971

130.268607

138.859307

146.053721

152.632825

All values in South African Rand (“ZAF”) were adjusted up to 2018 levels. Productivity losses
were calculated in US$ based on GNI per capita, Atlas method, adjusted to current USD and
therefore excluded from additional adjustment here.
Purchasing power parity (PPP): We considered the use of gross domestic product (GDP)
purchasing power parity (PPP) to assess impact relative to an international $ (i.e., a comparison
of a standard ‘basket of goods’ across countries). As we standardized all costs to the US$, the
relevant currency for our audience, we did not believe PPP comparison would add value to this
analysis. However, international $ may be a meaningful metric when comparing impacts of RVF
across multiple countries with widely different currency values and spending power, e.g. in SubSaharan Africa.
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RESULTS

Expenditures and losses
Table A2.2 Cost items associated with RVF, disaggregated by expenditures and losses incurred
Expenditures
-Medical treatment
-Transport
-Pharmacy
-Outbreak response services: outreach, sample
collection, transport, testing, contact tracing
-Arbovirus surveillance
-Disinfection and control
-Vaccination
-Meetings

Losses
-Forgone income
-Reduced animal stock
-Reduced meat and milk yield
-Reduced sales or pricing of livestock products
-Forgone hunting and game meat revenue
-Forgone tax revenue

Disability-adjusted life year and productivity measures
DALYs
Selection of disability weights. Disability weights may change over time; for example, LeBeaud et al.
estimated aggregate burden of RVF in Africa using a disability weight of 0.62 for prolonged neurological
complications based on the 1994 Global Burden of Disease disability weighting guidelines; the weight is
lower in the 2013 Global Burden of Disease study that we used. However, given that YLLs constituted the
majority of losses in both our study and Orinde’s findings, these changes are unlikely to alter estimates
significantly.
Methods for estimating YLL. We compared two methods of calculating YLL; 1) based on standard life
expectancy at birth for mean age of death and 2) based WHO-published life tables to determine remaining
life expectancy by age group in 2010. All deaths occurred in 2010.
1) Mean age of death for the 25 fatalities was 44 (personal communication, B. Archer/NICD). Based on
standard life expectancy at birth for 2010 for South Africa (57.67)(World Bank development indicator)
we estimated there were 13.67 years of life expectancy not attained for each premature death, i.e. 341.75
YLL.
2) Life tables are available for each year, grouped in 5-year age increments (i.e., 10-14, 15-19) and
disaggregated by male and female sex. We averaged across 5-year increments to match our 10-year
increment case fatality information. As sex distribution was not known for RVF fatalities, we used life
tables for males based on the known high ratio of male:female RVF cases overall (87%) (as reported
by Archer et al. 2013), assuming that most fatalities were male and as these yielded more conservative
life expectancy values (female LE was an average of 4.44 years higher than male LE for ages 1-84).
For one fatality listed as >70, we assumed they were in the 70-79 age range. For YLD, given lack of
age-specific information on clinical sequalae (and assumptions about clinical outcomes in general), we
estimated 4% of chronic disability persisted for the remainder of life, using the difference of the median
age of cases (43 as reported by Archer et al. 2013) and standard life expectancy at birth for 2010 for
South Africa (57.67). From this combined approach, we estimated there were 680.776 YLL.
Expected life remaining by age group is a more precise measure of life expectancy, reflecting annual
changes that take into account a number of factors, such as survival beyond certain high-risk life periods
(e.g. elevated risk of infant mortality, traffic fatalities in young adults, etc.) and modernization in health
services that may improve outcomes. This approach yielded a substantially higher estimate than based on
mean life expectancy alone. While 16/25 fatalities occurred in adults 40+, the 9 fatalities <40 constituted
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52% of YLL. While age- or sex-disaggregated information is not always available, our findings indicate
the utility of life tables, particularly where age is widely distributed.
Table A2.3 Life Tables, 2010. Data for females is shown in grey but was not included in our calculations.
Source: WHO. Shaded cells represent age groups with RVF fatalities (colors distinguish combined 5-year
age groups into 10-year age groups as a visual guide).

Indicator
ex - expectation of life at age x
ex - expectation of life at age x
ex - expectation of life at age x
ex - expectation of life at age x
ex - expectation of life at age x
ex - expectation of life at age x
ex - expectation of life at age x
ex - expectation of life at age x
ex - expectation of life at age x
ex - expectation of life at age x
ex - expectation of life at age x
ex - expectation of life at age x
ex - expectation of life at age x
ex - expectation of life at age x

Age Group
<1 year
1-4 years
5-9 years
10-14 years
15-19 years
20-24 years
25-29 years
30-34 years
35-39 years
40-44 years
45-49 years
50-54 years
55-59 years
60-64 years

ex - expectation of life at age x
ex - expectation of life at age x
ex - expectation of life at age x
ex - expectation of life at age x
ex - expectation of life at age x
Total (expected) life years lost

65-69 years
70-74 years
75-79 years
80-84 years
85+ years

2010

2010

55.6
57
54
49.5
44.9
40.3
35.8
31.8
28.2
25.3
22.4
19.4
16.5
13.6

Female
60.4
61.5
58.5
54
49.4
44.7
40.3
36.9
34
31.4
28.3
24.9
21.5
18.1

11
8.8
6.9
5.4
4.2

14.8
11.9
9.2
6.9
5.2

Male

#
Deaths
0
0
0

10-Year
Group Ave.

Expected
years

1

47.2

47.2

5

38.05

190.25

3

30

90

6

23.85

143.1

7

17.95

125.65

2

12.3

24.6

1

7.85

7.85

0
0
628.65

Productivity losses
Gross National Income (GNI) is a wealth measure of country earnings based on income rather than output
(Gross Domestic Product). While both are commonly used measure for disease-associated productivity
losses (and both are imperfect measures, e.g. they do not capture losses in leisure time that may result from
illness), GNI is typically considered more accurate by development funders given its inclusion of foreign
investment and foreign aid and has been used in several recent studies measuring economic burden (e.g.
from air pollution and other chemical exposures to hookworm infection).
It is important also to consider relative wealth and implications for economic resilience. South Africa ranks
among the countries with highest income inequality; farm workers often support immediate and extended
family members and their disability or death may have long-term consequences for familial economic
mobility. We used a GNI multiplier of 6 in our sensitivity analysis to reflect this relative impact.
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Healthcare utilization costs
Table A2.4 Estimated costs for medical care, South Africa (2010), by type of facility and currency unit.
Rows in yellow denote values selected for Table 2. Source: WHO-CHOICE.
Level
Outpatient
Cost per outpatient visit, Health Center (no beds)
(model prediction)
Cost per outpatient visit, Health Center (with beds)
(model prediction)
Cost per outpatient visit, Primary hospital (model
prediction)
Cost per outpatient visit, Secondary hospital (model
prediction)
Cost per outpatient visit, Tertiary hospital (model
prediction)
Cost per outpatient visit, Health Centre (no beds)
Cost per outpatient visit, Health Centre (with beds)
Cost per outpatient visit, Primary Hospital
Cost per outpatient visit, Secondary hospital
Cost per outpatient visit, Health Centre (no beds)
Cost per outpatient visit, Health Centre (with beds)
Cost per outpatient visit, Primary Hospital
Cost per outpatient visit, Secondary hospital
Cost per outpatient visit, Tertiary Hospital
Inpatient
Cost per inpatient bed day by hospital level, Primary
hospital (model prediction)
Cost per inpatient bed day by hospital level,
Secondary hospital (model prediction)
Cost per inpatient bed day by hospital level, Tertiary
hospital (model prediction)
Cost per inpatient bed day by hospital level (without
drugs), Primary hospital
Cost per inpatient bed day by hospital level (without
drugs), Secondary hospital
Cost per inpatient bed day by hospital level (without
drugs), Tertiary hospital
Cost per bed day, Primary hospital (model
prediction)
Cost per bed day, Secondary hospital (model
prediction)
Cost per bed day, Tertiary hospital (model
prediction)

Currency

Amount

2010 National Currency Unit (NCU)

65.70

2010 National Currency Unit (NCU)

81.1

2010 National Currency Unit (NCU)

92.4

2010 National Currency Unit (NCU)

96.3

2010 National Currency Unit (NCU)

96.3

2010 International Dollars (PPP I$)
2010 International Dollars (PPP I$)
2010 International Dollars (PPP I$)
2010 International Dollars (PPP I$)
2010 USD
2010 USD
2010 USD
2010 USD
2010 USD

14.65
17.44
14.65
20.58
8.97
11.07
12.62
13.15
13.15

2010 National Currency Unit (NCU)

577.00

2010 National Currency Unit (NCU)

601.51

2010 National Currency Unit (NCU)

777.92

2010 International Dollars (PPP I$)

129.99

2010 International Dollars (PPP I$)

137.45

2010 International Dollars (PPP I$)

175.67

2010 USD

78.81

2010 USD

82.16

2010 USD

106.25

Low-High

3.13-47.23
3.61-52.75
3.88-60.85
4.27-60.54

51.71283.55
49.57295.29
71.47360.99
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Other sources of impact data examined
Public Health and Veterinary Services response
Initially, we sought to extrapolate yearly costs of available aggregate outbreak response costs (see tables
below). However, these breakdowns were superficial and potentially misleading given the geographic
trajectory of the disease and likely enhanced attention during 2010, when the majority of human and
domestic animal losses were seen. In the absence of precise cost data by year, we grouped Public Health
and Veterinary Services costs for the 2008-2011 epidemic. We used 2010 as the reference year to adjust
for cost inflation.
Diagnostics
To approximate cost, we calculated per-sample cost based on PCR (R800), HAI (R124), and ELISA (R140)
testing for all 2,621 total human specimens collected and tested between 2008-2011 that led to the 302
laboratory-confirmed cases (see Table). As we did not know the breakdown of screening by year, an
estimate was derived using:

𝑆𝑦𝑒𝑎𝑟

(𝐶𝑦𝑒𝑎𝑟 ÷ 𝐶𝑡𝑜𝑡𝑎𝑙 )
⁄
𝑆𝑡𝑜𝑡𝑎𝑙
=
100

Where:
S=specimens tested
C=confirmed cases
year= given year
Total= all specimens tested
Table A2.5 Laboratory-confirmed human cases by year and province, 2008-2011 and 2018 outbreaks.
Year

Cases

Provinces with Human Cases

2008-2011 (3 tests/specimen conducted)
Gauteng, Mpumalanga,
2008
17
Limpopo
KwaZulu-Natal, Northern
2009
7
Cape
Free State, Northern Cape,
2010
241
Eastern Cape, Western Cape,
North West
Eastern Cape, Western Cape,
2011
37
Free State, Northern Cape
Total
302
All
2018 (4 tests/specimen conducted)
2018
6
Free State

Percentage of
Cases

Est. #
Specimens
Screened/Year

Total
Cost
(Rand)

5.63

148

157,472

2.32

61

64,904

79.80

2,092

2,225,888

12.25

321

341, 544

100.00

2,621

2,789,808

100

6

R12,000

Source: Case data from Archer et al. 2013 and Van Vuren et al.; test costs/year our calculations.
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Agriculture

Figure A2.1 Wool production per province, by year. Circle indicates main outbreak period and resulting
declines (losses may be deferred based on shearing season). Source: Cape Wools South Africa, 2014.
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Exports
Various livestock products are indictive of export flows and possible effects of trade bans. An
example is shown below for South African exports, by global trade and with the country’s major
purchaser of wool.
Table A2.6 Wool (greasy) trade flows, 2009-2014, World Integrated Trade Solutions (World Bank).
Nomen
clature

Code

Name

Product
Code

Partner
Code

Partner
ISO3

Partner
Name

Year

Trade
Flow
Name

Trade
Value in
1000 USD

Totals

World
H0

710

H0

710

H0

710

H0

710

H0

710

H0

710

South
Africa
South
Africa
South
Africa
South
Africa
South
Africa
South
Africa

510111

0

WLD

World

2009

510111

0

WLD

World

2010

510111

0

WLD

World

2011

510111

0

WLD

World

2012

510111

0

WLD

World

2013

510111

0

WLD

World

2014

510111

156

CHN

China

2009

510111

156

CHN

China

2010

510111

156

CHN

China

2011

510111

156

CHN

China

2012

510111

156

CHN

China

2013

510111

156

CHN

China

2014

Gross
Exports
Gross
Exports
Gross
Exports
Gross
Exports
Gross
Exports
Gross
Exports

144,430

144,429,788

166,333

166,332,870

271,431

271,430,811

278,594

278,593,994

290,254

290,254,302

248,164

248,164,275

109,482

109,482,368

62,717

62,716,724

112,183

112,182,878

176,324

176,323,530

194,816

194,816,210

186,390

186,389,620

China
H0

710

H0

710

H0

710

H0

710

H0

710

H0

710

South
Africa
South
Africa
South
Africa
South
Africa
South
Africa
South
Africa

Gross
Exports
Gross
Exports
Gross
Exports
Gross
Exports
Gross
Exports
Gross
Exports

Source:

http://wits.worldbank.org/WITS/WITS/QuickQuery/ComtradeByProduct/ComtradeBy
Product.aspx?Page=COMTRADEByProduct

Nomenclature:

HS 1988/92

Flow:

Gross Exports

Tier

Sub-headings (6-digit)

Product

Greasy wool
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Table A2.7 RVF incidence per province (per 100,000 animals) (from Glancey et al. 2015).
2008
Province

Cattle

Limpopo

2.33

Gauteng

12.6

91.97

23.89

1.98

Mpumalanga
KwazuluNatal
Northwest
Free State
Eastern Cape
Northern
Cape
Western
Cape

Goats

2009
Sheep

Cattle

Goats

2010
Sheep

Cattle

Goats

2011
Sheep

Cattle

Goats

Sheep

0.02
0.38

8.56

3.38

11.77

7.22
4.54

1.45

0.68

24.11

17.22

29.38

188

1.16

0.99

6.5

1.58

5.07

8.22

344.2

0.06

38.69

15.49

12.54

2.16

3.81

26.67
120.99

108.18

25.45

Animal feeds. While reasonable to assume that animal mortalities may reduce volume of feed purchased,
the potential significance is dependent on extent of farms’ existing use of grazing resources and was
beyond the scope of our analysis.
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Aim 3: Additional considerations for survey data
Survey instrument
Willingness to Pay Survey

Farm ID

Gray text is not visible to the person taking the survey, but in place to assist with the flow in paper format (vs how
it will be given as part of the app on a tablet).
To be filled out by survey administrator:
Admin 1. Scan the barcode for the associated record
Admin 1a. Enter the barcode manually.
If scanning the barcode is not possible:
Admin 2. Farm Identifier:
Admin 2a. Farm Name:
Admin 3. Date of interview:
Admin 4. Collect the current GPS coordinates.
Admin 4a. Enter the latitude and longitude manually using the GPS.
If automatic GPS coordinate does not work then:
Latitude (Degrees) ________
Latitude (Minutes) ________
Latitude (Seconds) ________
Longitude (Degrees) ________
Longitude (Minutes) ________
Longitude (Seconds) ________
Admin 5. Filled in by: _________
The remainder of the survey should be filled out by the participant.
1. How much would you be willing to pay today to prevent animals in your herd aborting or dying from Rift
Valley fever? Please state the total amount for your farm: _________
2. How much would you be willing to pay each year for the next 10 years to prevent animals in your herd
aborting or dying from Rift Valley fever? Please state the total amount for your farm:________
3. We are now going to ask you about how much you would be willing to pay to vaccinate your herd against
Rift Valley fever in different situations. For each situation, please state the total amount for your farm that
you would be willing to pay.
3a. How much would you be
willing to pay to prevent animals
aborting or dying from Rift Valley
fever
if you thought the risk of Rift
Valley fever circulating in
mosquitos was low for your
province?

3b. How much would you be
willing to pay to prevent animals
aborting or dying from Rift
Valley fever
if you thought the risk of Rift
Valley fever circulating in
mosquitos was high for your
province?

3c. How much would you be willing
to pay to prevent animals aborting
or dying from Rift Valley fever
if you thought the risk of Rift Valley
fever circulating in mosquitos was
high for your farm?

4. If you thought risk of an Rift Valley fever outbreak was high in your province, would you take any other
measures (in addition to or instead of livestock vaccination) to avoid impact from the disease?

Willingness
Pay
(2018)|
VALLEY FEVER SURVEY
Version to
1.0,
dated
MayRIFT
3, 2018

Hummingbird IRB
Approved
05/03/2018

1
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Willingness to Pay Survey

Farm ID

a.
Yes
No
b. If yes, please select the measure(s): select all that apply
Dipping (mosquito repellant- please list product name________________)
Terramycin
Other, please list:____________
c. How much do you estimate these measure(s) would cost you?
i.
Per animal: _________ ii. For your farm: _________
5. How much would you be willing to pay to vaccinate animals so that people do not get sick from Rift Valley
fever?
Please state the amount:____________ (zero to any amount)
6. Are you currently vaccinating against Rift Valley fever (vaccination in the past year)?:
Yes (if yes, please go to question 7).
No
a. If No, what is the main reason you do not or would not vaccinate your animals against Rift Valley
fever? Please select one:
It costs too much
It takes too much time to bring the animals in and administer the vaccine
I do not think it will protect my animals
I do not feel there’s a risk of my farm being infected
Vaccination is not required to sell my animals/animal products
Other, please specify:_________
b. What is the second most important reason you do not or would not vaccinate your animals against
Rift Valley fever? Please select one:
It costs too much
It takes too much time to bring the animals in and administer the vaccine
I do not think it will protect my animals
I do not feel there’s a risk of my farm being infected
Vaccination is not required to sell my animals/animal products
Other, please specify:_________
7. Would any of these factors make you more likely to vaccinate your herd against Rift Valley fever in any
given year? Please select all that apply:
An alert from the government suggesting higher than normal risk for a Rift Valley fever outbreak
Government pays for some of the vaccine cost
Vaccine is in stock and available to purchase at local farm supply store
Your neighbors vaccinate their herds
There is more rainfall than usual
Other, please list:______________
8. Do you feel there is a sufficient supply of the vaccine if you wanted to wanted to vaccinate your herd each
year?:
Yes
No
a. In general:
b. During an outbreak:
Yes
No
9. How much would you be willing to pay each year for the next ten years for insurance to protect against
each of these specific losses to your farm?:
a. Theft of livestock: ________
b. Outbreak of Rift Valley fever: ________
c. Outbreak of Chlamydophila abortus:_________
d. A drought: ________
Thank you for participating in the survey
*Please note that Rift Valley fever virus is not treatable with any
antibiotics, including Terramycin

Willingness
Pay
(2018)|
VALLEY FEVER SURVEY
Version to
1.0,
dated
MayRIFT
3, 2018

Hummingbird IRB
Approved
05/03/2018
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Per-animal estimates
One question (Question 4, on other control measures in addition to or instead of vaccination) requested
both per-animal and per-farm WTP responses. To assess validity of calculating a per-animal estimate
for other measures, we compared per-animal responses to Question 4 to our manual calculation (WTP
measure/Average number of domestic animals):
• Per-animal stated by farmer: Mean stated WTP per-animal was R16.48 (US$1.33) (103
observations);
• Comparison to our calculations based on average number of domestic animals on farm: R10.20
(US$.70) (97 observations).
Our calculations were roughly 50% of farmer-stated per-animal WTP for question 4. There are several
possible explanations: missing observations that restricted available farms for calculations; some farms
reported they had zero domestic animals on their farm (whether reflecting their situation at the time,
perhaps due to the severe drought the prior years, a change in their production system, or transient
stock); and most likely variation in the number and species of animals vaccinated each year (e.g. sheep
vs. cattle, juveniles vs. adults, one-time versus annual vaccination, etc.) Each of these factors is likely
highly variable by farm and by year given other competing priorities. Therefore, these factors likely
make total (or average) number of domestic animals on the farm a poor approximator of the number
of animals prevention measures would be applied to in any given year.
While we provide per-animal estimates and see their utility for comparing to other studies
(especially the only other WTP study for RVF vaccination conducted to date), our per-farm estimates
are likely more valid and useful for policy makers seeking to target available on-farm and provincial
resources to maximize resource effectiveness. For example, the state-linked vaccine producer in South
Africa, Onderstepoort Biological Products (OBP), supplies numerous livestock vaccines and may
consider pricing offerings in accordance with total farm budgets; similarly, veterinary services and
public health departments may use this information to identify provincial budget needs.
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Dip/Insecticides/Antiparasitic Products
In South Africa livestock ‘dipping’ is a common measure for control of agricultural diseases
across production systems. A range of products are marketed for use. The list below reflects
brand names farmers mentioned when asked about use of dip/insecticide or indicating “Other”
control measures they would take if they thought RVF risk was high in their province.
Table A3.1 Product names mentioned by farm owners for other control measures they would take if they
thought risk of RVF was high in their province.
Product Name
Group
Primary use
Delete-X5
Pyrethrins and Pyrethroid
Oraganophosphors, Pyrethrins and
Zeropar
Pyrethroid
Phenylpyrazole and macrocyclic lactones
Attila
Drastic Deadline
Pyrethrins and Pyrethroid
Zipdip
Organophosphors and carbamates
Supona 30 Cattle dip
Organophosphors and carbamates
Control of
Dazzle NF
Organophosphors and carbamates
mites/midges,
Copperzon 30
Organophosphors and carbamates
ticks, lice, and/or
Triatix Plus Pour-On
Pyrethrins and Pyrethroid
flies*
Triatix 125
Pyrethrins and Pyrethroid
Dectospot
Pyrethrins and Pyrethroid
Amipor
Pyrethrins and Pyrethroid
Ecobash
Pyrethrins and Pyrethroid
Paracide
Pyrethrins and Pyrethroid
Pro-Dip Cyp 20%
Pyrethrins and Pyrethroid
®
Pyrethrins and Pyrethroid
Delete All
Ectoshield
Pyrethrins and Pyrethroid
Dectomax® Pour-On Endectocide
Dectomax® Injectable Endectocide
Macrocyclic lactones
Antiparasitic
Cydectin® Injectable
*May also have antiparasitic properties.
Table A3.2 Example of specific usage information and potential human and environmental health
impacts.
Name
of Dip

Zipdip

Active
ingredient

Triazophos
40% m/m

Application
method

Spray dip,
Plunge dip

Animals

Used for

Sheep,
goats and
pigs

Kills sheep scab mites,
lice, keds, blowfly larvae
and control ticks present at
time of dipping and itch
mites on sheep and goats.
Control Karoo Paralysis
ticks. Kills mange mites in
pigs.

Human and
environmenta
l impact
Poisonous by
contact,
swallowing
and inhalation.
Toxic to fish,
bees, poultry,
birds and
wildlife.

Withdrawal
period

Meat: 7 days
after last
application

Source: Product details and health and environmental impacts compiled by L. van Staden,
ExecuVet (Pty) Ltd., Bloemfontein, South Africa/RVF One Health economics project researcher.
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